```
Page 1
 1
              UNITED STATES DISTRICT COURT
               NORTHERN DISTRICT OF FLORIDA
 2
                  TALLAHASSEE DIVISION
 3
     AUGUST DEKKER, et al.,
 4
          Plaintiffs,
 5
     V.
                            Case No. 4:22-cv-00325-RH-MAF
     JASON WEIDA, et al.,
 6
 7
         Defendants.
 8
     DEPOSITION OF: MATTHEW BRACKETT
9
                         WEDNESDAY, MARCH 8TH, 2023
     DATE:
10
                         10:00 A.M. - 11:44 A.M.
     TIME:
11
                         REMOTE PROCEEDINGS
     PLACE:
12
13
     STENOGRAPHICALLY
     REPORTED BY: LAWANDA MERCER
14
15
16
17
18
19
20
2.1
22
23
24
25
```

```
Page 2
     APPEARANCES:
1
     Katherine Jean Ann DeBriere, ESQUIRE
 2
     Simone Chriss, ESQUIRE
 3
     OF: Florida Health Justice Project
         3900 Richmond Street
         Jacksonville, Florida 32205-9330
 4
         352-496-5419, FAX-352-496-5419
         Debriere@floridahealthjustice.org
 5
         Simone.Chriss@southernlegal.org
         APPEARING ON BEHALF OF THE PLAINTIFF
 6
 7
     Gary Vergil Perko, ESQUIRE
     OF: Holtzman Vogel, et al
         119 S Monroe Street, Ste 500
 8
         Tallahassee, Florida 32301-1591
 9
         850-391-0502, FAX-850-391-0502
         Gperko@holtzmanvogel.com
10
         APPEARING ON BEHALF OF THE DEFENDANT
11
     ALSO PRESENT:
12
     Andrew Sheeran, Esquire
13
     Jennifer Altman, Esquire
     Shani Rivaux, Esquire
     Chelsea Dunn, Esquire
14
     Catherine McKee, Esquire
15
16
17
18
19
20
21
22
23
2.4
25
```

	Page 3
1	I N D E X
2	TESTIMONY OF MATTHEW BRACKETT
3	DIRECT EXAMINATION BY MS. DEBRIERE5
4	CERTIFICATE OF OATH55
5	CERTIFICATE OF DEPOSITION TRANSCRIPT56
6	ERRATA SHEET57
7	NOTIFICATION LETTER58
8	
9	INDEX OF EXHIBITS
10	PLAINTIFF'S
11	(DESCRIPTION) PAGE NO.
12	Exhibit 24 (Written responses) 5
13	Exhibit 25 (AHCA Summary of Public 25
	Comments in Response to the GAPMS
14	at issue in this case)
15	Exhibit 26 (Errata sheet) 42
16	
17	STIPULATIONS
18	It is hereby stipulated and agreed by and between
19	the counsel for the respective parties and the deponent
20	that the reading and signing of the deposition
21	transcript be reserved.
22	
23	
24	
25	

Page 4 PROCEEDINGS 1 \*\*\*\*\* 2. 3 THE VIDEOGRAPHER: This is the continued video-recorded deposition of Matthew Brackett in the 4 5 matter of August Dekker, et al. v. Jason Weida, et 6 al, Case No.: 4:22-cv-00325-RH-MAF. deposition is being held at 2727 Mahan Drive in Tallahassee, Florida. Today's date is March 8th, 8 9 2023, and the time is 10:09 a.m. The court reporter 10 is Lawanda Mercer. My name is R.L. Minnich, I'm the 11 videographer. 12 Would counsel please introduce themselves and 13 then the court reporter please swear in the witness. 14 Yes. Katy DeBriere, counsel for MS. DEBRIERE: 15 Plaintiffs. 16 MS. CHRISS: Simone Chriss, counsel for 17 Plaintiffs. 18 MR. PERKO: Gary Perko, Counsel for Defendants. 19 MS. DEBRIERE: And on the line, we have several 20 counsel for Plaintiffs, including Jennifer Altman, 21 Catherine McKee, Shani Rivaux and Chelsea Dunn. 2.2 MR. SHEERAN: And Andrew Sheeran of the Agency 23 is on the phone. 24 COURT REPORTER: Sir, please raise your right 25 hand.

```
Page 5
              Do you solemnly swear, or affirm, the testimony
 1
 2.
         you're about to give today is the truth, the whole
         truth and nothing but the truth?
              THE WITNESS: I do.
 4
 5
              COURT REPORTER:
                                Thank you.
 6
                          MATTHEW BRACKETT,
 7
     having been produced and first duly sworn as a witness,
     testified as follows:
 8
 9
                       DIRECT EXAMINATION
10
     BY MS. DEBRIERE:
11
              Okay, Mr. Brackett. So, on March 6th, 2023,
12
     your counsel provided us a copy of written responses to
13
     our questions. And that was in -- in follow-up to
14
     your -- the first part of this deposition on
15
     February 8th. I'm going to mark those responses as
16
     Exhibit 24 and hand you this.
              (Thereupon, Plainitiff's Exhibit No. 24 was
17
     marked for identification.)
18
     BY MS. DEBRIERE:
19
20
              Do you recognize this document?
         Q.
21
         A.
              Yes, I do.
22
              And are these your responses?
         Q.
23
              Yes, they are.
         A.
              Okay. And we talked about this a little bit
24
         O.
2.5
     before --
```

800-726-7007 305-376-8800

Page 6 1 MS. DEBRIERE: Here you go, Gary. 2. MR. PERKO: Oh, thank you. 3 BY MS. DEBRIERE: Just a little bit before the deposition 4 5 started. But in the second question, I just wanted to 6 correct one thing that was my mistake. The hyperlink we 7 provided for the drug criteria in our question No. 2, it did not work. I wanted to go back to the web page now 8 and show it to you and then read off the URL in the 9 10 transcript. And that way we can just agree that's the 11 one that contains the exhaustive list. Is that okay 12 with you? 13 That's okay, yeah. 14 Okay. So is the exhaustive list of drug Ο. criteria contained in this document titled "Preferred 15 16 Drug List"? Oh, no. 17 Α. No. 18 That's not it. Sorry. My fault here. Give me Ο. 19 one second. 20 COURT REPORTER: For the record, which attorney 21 is speaking? 2.2 MS. DEBRIERE: Katy DeBriere for the 23 plaintiffs. 24 COURT REPORTER: Thank you. 25 MS. DEBRIERE: Okay.

Page 7 1 BY MS. DEBRIERE: 2 0. Okay. So is this the web page that contains the exhaustive list of drug criteria --3 That is the web page. 4 A. 5 0. -- for AHCA? Okay. 6 A. Yes. And just to -- for the clarification of the 7 0. 8 record, that URL is AHCA, a-h-c-a. 9 http://ahca.myflorida.com/medicaid/prescribed\_drug/drug\_ 10 criteria.shtml. 11 Okay. Thank you. All right. Turning to the 12 auto PA that you link in the response to your first 13 question. We appreciate that written explanation. 14 Quick set of follow-ups: If a drug is denied on the 15 basis of auto PA, does the beneficiary receive 16 notice of that denial? 17 So it would automatically go to a PA. 18 recipient would learn at the pharmacy that it was being 19 auto PA'd, yes. 20 -- Okay. Do they receive notice of the denial? Q. It's for, like, a NABD? 21 Α. 2.2 Yes. Or a pharmacy notice of some sort? O. 23 Well, the pharmacy would definitely verbally I don't believe they would receive a written 24 tell them. notice just because their drug is being auto PA'd 25

Page 8

- because it's not officially a denial. It's being kicked to auto prior authorization process.
- Q. Okay. So it's your understanding they do not receive a written -- a written denial?
  - A. That's my understanding.
- Q. Okay. Could the -- they, or in this instance the prescribing drug pro -- the provider who's prescribing the drug, could they resubmit their request for a prior authorization using the clinical PA process, if denied on auto PA?
- A. So the prescriber would have to go through and refill the prescription if --
  - Q. Refill the prescription or re --
- A. Or re -- reissue the prescription if it's -- goes through auto PA.
- Q. Okay. Would the person then have the -- the -- would the Medicaid beneficiary then have the opportunity to take that new prescription and submit it for clinical prior authorization, if it was denied on auto PI -- PA?
  - A. They can. It would --
  - Q. Okay.
    - A. It would go to the pharmacy.
- Q. Okay. How -- if -- so, if that's the case, how does AHCA then determine if the prior authorization is approved? What criteria do they use?

1

2.

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

Page 9

- A. So that would, of course, be a case-by-case basis. And it would be in accordance with our medical necessity guidelines, yeah.
- Q. Would you also use the drug criteria at the URL we just read off?
  - A. Yes, we would.

1

2.

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

- Q. Okay. Would it -- would you also compare it against the auto PA list, if it was already denied for auto PA? Would you do a manual review, I guess, I'm asking, of the auto PA list?
- A. Prior -- prior authorizations are manual reviews.
- Q. Auto prior authorization is not a manual review, correct, it's automatic?
- A. It pretty much means that it's automatically referred to prior authorization.
- Q. Is there someone who's physically reviewing the criteria for prior auth -- authorization under auto PA?
  - A. So --
  - Q. Or it's the computer program?
- A. -- the prior authorizations, those, of course, are reviewed by Magellan. Those are reviewed manually.
- Q. Okay. Is that a -- what I'm trying to
- understand is when Magellan is doing the review
- 25 manually, is that only for clinical PAs or is that also

Page 10 1 for auto PAs? That would be for the clinical PA. 2 A. Okay. But not for the auto PA? 3 0. The auto PA would be, of course, automatic. 4 A. 5 Great. Okay. Okay. I just want to give you a 0. 6 hypothetical real quick, looking at the auto PA list. 7 So looking at Page 27 here of the auto PA -- A list, and this is the auto PA list that you provided to us linked 8 9 in your written responses. For Lupron Depot, let's 10 imagine a pro -- a provider has prescribed Lupron Depot-PED to treat a condition not listed in list B here 11 12 on Page 27. Let's also assume the condition that it's 13 prescribed for is not gender dysphoria. If the prior 14 authorization request is denied through auto PA, could a 15 provider submit the clinical P -- PA process and show 16 that the coverage is nevertheless required under EPSDT? 17 They can do that. A. 18 Okay. All right. On February 8th, you 0. 19 testified that AHCA's Medicaid Program Integrity Unit 20 undertakes a rest -- retrospective claims review. Do 21 you remember that? 22 A. Yes, I do. 23 Okay. And that retrospective claims review is 0. 24 of whether prescribed drugs that don't require prior -any prior authorization were prescribed for a medically 25

Page 11 1 necessary reason. Do you recall that testimony? 2 A. I do recall that. 3 Okay. So I just have some follow-up questions about that retrospective review process. The point is 4 5 to ensure that Medicaid dollars in that retro -retrospective review process, the point is to ensure 6 7 that Medicaid dollars aren't being used fraudulently, 8 correct? 9 A. Correct. 10 Okay. Does AHCA do that retrospective review 0. 11 for every single claim paid? 12 A. It does not. 13 0. Okay. When it does do the review on -- so 14 it -- it only does a retrospective review on select 15 drugs; is that correct? 16 It does retrospective reviews when the 17 situation calls for it. So if there's suspected fraud, 18 it could do a retrospective review. If there's 19 suspicion of overpayments through humans might be not 20 needed. It's basically on an ad hoc basis as needed. Okay. Okay. Sorry. So when it's doing that 21 22 retrospective review, what criteria does AHCA use to 23 determine if the claim should not have been paid? A. So if -- of course, it would look at the 24 recipient, look at their diagnosis codes, look at their 25

Page 12 1 his -- medical history, and look -- and they would evaluate to determine whether those services that are 2 being delivered and claims reimbursed for are necessary 3 for the needs of that specific recipient. 4 5 And if you find that the drug was prescribed for in -- in this ad hoc retrospective review process, 6 7 if you find that the drug was prescribed for something 8 that was not medically necessary, what is the 9 consequence to the pharmacy, if any? 10 To the pharmacy, since the pharmacy just 11 dispenses the drugs, I don't think we would have any 12 consequences to the pharmacy. It would be on the pro --13 on the prescriber. 14 Okay. So you wouldn't take Medicaid dollars 15 back from the pharmacy who is reimbursed for dispensing 16 the drug? 17 A. I don't believe we would. 18 Okay. Just going back to my hypo real quick. 0. 19 On the Lupron Depot, you said that if the PA request is 20 denied through auto PA, the provider could submit through the clinical PA process and show that the 21 22 coverage is nevertheless required under EPSDT. Is that 23 correct? 24 A. Yes. Okay. In that instance, is there the 25 Q.

Page 13 1 possibility that the drug could be covered under EPSDT? 2 A. Any FDA-approved drug could, potentially, be 3 covered under EPSDT, that's correct. Okay. In that clinical PA review process? 4 Q. 5 A. Yes. 6 0. Okay. What percentage of prescription drugs 7 claims paid undergo retrospective review turning back 8 (inaudible)? 9 A. We don't have that information offhand. 10 0. Okay. Is that information you could get us? 11 I don't know if we could, actually, get that A. 12 information. 13 But again, your understanding is it's not every 14 drug that's dispensed, without the need for a prior 15 authorization is then subject to a retrospective review? 16 Retrospective reviews don't happen in -- in 17 the -- in the cases of most claims. 18 Okay. Okay. Could I look at what was Q. 19 previously marked as Plaintiff's Exhibit 19? And these 20 are e-mail exchanges between AHCA and Magellan dated April 20th, 2022, to June 3rd, 2022. Looking back at 21 your written responses -- so thank you for telling us 22 what CCM stands for. What does Change Control Memo 23 24 mean?

25

Α.

So a change control memo, it's -- works like

Page 14 a -- a file maintenance for our CPT Codes, is that when 1 2. we need Magellan to make an update into its system, as 3 far as processing claims go, the analyst would create a Change Control Memo and send it to Magellan. And they 4 5 would use that as the basis to update their system. if maybe, like, a new NDC needs to be added. 6 7 like that. Okay. Have we been provided a copy of the 8 Ο. 9 particular CCM or Change Control Memo that's being 10 referenced in this e-mail? 11 I don't know if that document has been provided Α. 12 to you. 13 Q. Okay. 14 Gary, can we find that out? MS. DEBRIERE: MR. PERKO: We'll -- we'll find it. 15 16 MS. DEBRIERE: Thank you. And if you do find 17 it, you'll provide it to us? 18 MR. PERKO: Yes. 19 MS. DEBRIERE: Thank you. 20 BY MS. DEBRIERE: 21 Okay. Who provided the internal gender die --2.2 dysphoria criteria to Magellan for use, when reviewing 23 prior authorization requests for GN -- GnRH (inaudible)? So, at the time, that would have been the 24 Α. Bureau of Medicaid Policy. 25

Page 15

- Q. Okay. Why wasn't that criteria clo -- publicly posted?
- A. That -- of course, since that was almost seven years ago, the -- and the staff who were -- made that determination are no longer with us. The agency doesn't -- cannot recall why that occurred.
- Q. Okay. But all drug criteria should be publicly available?
  - A. No, they don't absolutely have to be.
- Q. Okay. As you earlier testified just now what was previously marked as Plaintiff's Exhibit 4, the exhaustive list of --
  - A. Uh-huh.

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

- Q. -- internal -- I'm sorry. Scratch that.

  What was previously marked as Plaintiff's

  Exhibit 4, which is the GnRH -- hold on, Mr. Brackett,

  I'll get you a copy of it. The Special Services

  Criteria For Pubertal Suppression with GnRH Analog.
  - A. Okay.
- Q. This represents the internal criteria AHCA provided to Magellan; is that correct? -- that's being referenced in this e-mail?
  - A. Uh-huh. That's correct.
- Q. Okay. Should this criteria have been publicly posted?

Page 16

- A. It does not have to necessarily be publicly posted. Just because what we have on our list currently is exhaustive, doesn't preclude us from not necessarily publicly posting one.
- Q. Okay. But just to be clear, the drug criteria that's posted at the website we read earlier, that is the exhaustive list, right?
  - A. That's currently exhaustive, yes.
- Q. Turning back to the e-mails. In 2017, why did AHCA direct the removal of all gender codes from programming?
  - A. Can you give me -- tell me the date again?
  - Q. Yep. Yep. So it's 2017.
- A. Uh-huh.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

- Q. Specifically, Elicia King-Wilson from Magellan writes to Susan Williams and others to ah -- from AHCA,

  "As a reminder, all gender codes were removed from"

  program -- "programming as directed by the Agency in

  2017."
  - A. So the gender codes prim -- what that means is that drugs can apply to either male or female. So it -- removed those and just it can apply to both genders.
    - Q. And that was the change made in 2017?
    - A. That was the change made in 2017.
      - Q. Okay. So that resulted in all products within

Page 17 the database being coded as 1 2. MEDICAID STATE VALID SEX CD=B-Both. 3 Α. Correct. (Inaudible). Okay. In June 22nd, 2022, why 4 5 did Arlene Elliott at AHCA direct Magellan to remove the Gender Code B-Both from all the NDCs that had it hard 6 7 And I can point you to the specific language, if helpful, in the e-mail. 8 9 Α. Yes. 10 So on the first page -- oh, I see. I 11 apologize. I misspoke. That was not in June, 2022, 12 that they were directed to remove the gender code. It 13 was on August 21st of 2017; is that correct? 14 That would be correct, yes. Α. 15 Ο. Okay. And that was done, again, to result in 16 all products having the Gender Code of B for Both; is 17 that correct? 18 That's correct. Α. Okay. Were there any changes to that made in 19 Ο. 20 2022? 21 Well, following the promulgation of the 2.2 challenge exclusion --Uh-huh. 23 Ο. -- yes. Those codes would have been updated to 24 reflect the changes that would make it align with the 25

Page 18 challenge exclusion. 1 2. Ο. Okay. And is that what the Change Control Memo 3 directed Magellan to do? We would use a Change Control Memo to have 4 Α. 5 Magellan update its symptoms. Okay. On -- okay. When did AHCA direct 6 7 Magellan to remove the Gender Code equals B-Both to implement the adoption of the categorical exclusion? 8 9 Α. That change would be intended to take effect on 10 the date the rule went into effect. 11 Okay. So you direct -- and -- and that date Ο. 12 was August 21st, 2017? 13 Α. I recollect that's correct. So at the -- what date would -- what date did 14 Ο. 15 AHCA direct Magellan to make that change? 16 It would have been a date preceding August 21st 17 since Magellan would need advanced notice. We don't have the date offhand. 18 19 Okay. Could you get us that date? O. 20 We -- we can look into it. Α. 21 Okay. Is this an e-mail directing Magellan to Ο. 2.2 make the change? Is this e-mail referencing -- scratch 23 that. 24 Is Exhibit 19, is this an e-mail from AHCA to Magellan asking them to make the change?

Page 19 Let me take a look --1 Α. 2. Ο. Yeah. 3 -- at it again. This does not appear to be Α. that e-mail. 4 5 Okay. Would there have been another e-mail 6 from AHCA to Magellan directing them to make that 7 change? It may have, potentially, been a verbal 8 Α. 9 request. 10 Okay. Can you verify that it was -- whether it Ο. 11 was an e-mail request or a verbal request for us, at 12 some point? Is that a follow-up that you can do? 13 MR. PERKO: I don't know if he can do it or 14 not. 15 THE WITNESS: I'm -- Im not sure because 16 Ashley Peterson, who used to have that role, is no 17 longer with us. 18 BY MS. DEBRIERE: But you could search Ashley Peterson's e-mails? 19 20 We can -- yeah. If there is an e-mail -- if Α. there was an e-mail for it, with all the searches we've 21 22 done for e-mails, it's probably been pulled up in that. 23 Okay. When Elicia from Magellan -- so turning Ο. back to the e-mail -- when Elicia from Magellan states 24 that all requests for GN -- and she's referencing GN --25

Page 20 GnRH Analogs use to delay puberty in the treatment of 1 gender dysphoria, were required to be vetted by AHCA 2. before a final determination is made. What did she mean 3 by that? 4 5 MR. PERKO: Can you point to the specific 6 language? 7 MS. DEBRIERE: Absolutely. BY MS. DEBRIERE: 8 9 Ο. So, looking at the e-mail from 10 Elicia King-Wilson dated April 20th, 2022, to Susan 11 Williams and others at AHCA, she states, "This internal 12 document serves for GnRH Analogs use to delay puberty in 13 adolescence with Gender Dysphoria, but it does not speak to the use of hormone therapy. This document was 14 provided by the Agency due to a fair hearing request for 15 16 Lupron for recipients with this diagnosis. All requests 17 required vetting by AHCA before a final determination is made and MMA will continue to do so as instructed." 18 19 Well, vetting by AHCA would -- could be Α. 20 interpreted as meaning that once Magellan has made its 21 determination, it would be sent to AHCA to be reviewed 2.2 and then returned to Magellan with a yes or no. Okay. So AHCA was making a -- a determination 23 0. on all requests sent to Magellan, as to whether or not 24 GnH -- GnRH Analog for the treatment of gender dysphoria 25

Page 21 was medically necessary? 1 2 A. Yes. 3 Okay. And do you know if AHCA ever said yes in 0. that situation? 4 5 We don't have a running list of when we would 6 say yes or no. So you don't know? Q. We don't know. 8 Α. 9 Okay. So these decisions would not have been Ο. 10 documented somewhere? 11 Not on any shared files, no. Α. 12 What other type of files would there be? Q. 13 Α. If a -- potentially if an -- an employee --14 potentially, if an employee kept a personal file or that would -- that would be it. 15 16 Okay. Were there -- are there any particular 17 employees who might keep those personal files that you can think of? 18 19 One of our pharmacists, potentially, may have 20 kept one. 21 Q. Okay. 2.2 But given that the pharmacists often share work 23 between them, and I don't think that they would have because there's -- there's no way that mid -- could --24 you get to determine whether or not that's a complete 25

Page 22 1 list, and other pharmacists may have vetted one, and it 2. may not have been recorded. 3 Who is the pharmacist you had in mind who might have it? 4 5 It's potentially, since this is historic, Susan Williams and Kelly Rubin, who were at the time --6 who were here at the time and -- and Susan Williams was on the e-mail chain. They are still employed with the 8 9 agency. 10 Is Susan Williams still employed with the Ο. 11 agency? 12 Susan Williams is still employed --Α. 13 O. Okay. 14 -- with the agency. Α. 15 Ο. So can you ask her if she has any of those 16 decisions documented somewhere? 17 Α. We can ask her. 18 Okay. And -- and then get -- provide us the Ο. 19 answer? 20 Α. Okay. Okay. When AHCA was making these 21 0. 22 determinations, what criteria were they using? So when AHCA was making its determinations, of 23 A. course, it's going to be in line with our internal GnRH 24 Analog for Gender Dysphoria Criteria. 25

Veritext Legal Solutions

Page 23 1 And that's what was previously marked as 2 Plaintiff's Exhibit 4? 3 A. That's correct. Okay. When Elicia references MMA, does MMA 4 Ο. 5 stand for Managed Medical Assistance? That's correct. 6 Α. 7 Okay. And Managed Medical Assistance is AHCA's Q. Managed Care Program for Florida Medicaid, correct? 8 9 Α. It's one of our Managed Care Programs, that's 10 correct. 11 So it's referencing -- when she says MMA, she's Ο. 12 referencing all Managed Care Plans, excluding Long-Term 13 Care Plans; is that correct? 14 She's referencing all plans that have an MMA 15 contract, yes. 16 Okay. And all plans that have an MMA contract, Ο. 17 that's publicly available on AHCA's website, correct? This would have been actually with our first 18 Α. contract period. So at the time --19 20 Q. Uh-huh. 21 -- because we did a re-procurement in 2018 --Α. 2.2 Ο. Uh-huh. 23 -- and we had a new contract period, these contracts would be historical. That's not available on 24 25 our web pages right now.

Page 24

- Q. So what plans had MMA contracts at the time?
- A. Staywell, Sunshine, Molina, Prestige. That's just the ones I can think of off the top of my head.
  - Q. Humana?

1

2.

3

4

5

6

7

8

10

11

12

13

14

15

16

17

18

19

20

21

22

- A. Humana was one. Aetna.
- Q. And that -- Sunshine and Staywell, that would include any of the specialty plans they operated as well?
- A. This would apply to the specialty plans as well.
  - Q. Okay. Including Children's Medical Services?
- A. That's correct. But that wasn't a Managed Care during this contract period.
  - O. 2017. So that was operated by at the time?
  - A. At -- Department of Health operated Children's Medical Services. It didn't get -- get -- it wasn't until the second contract period. That was when CMS -- that's when Staywell took over CMS.
  - Q. But this criteria -- or this requirement that we've been discussing that AHCA vet every request for use of GnA -- GnRH antagonist by an adolescent for the treatment of gender dysphoria, they would also apply to use CMS, correct?
- 24 A. Yes.
- Q. Okay. Okay. So turning to the AHCA Summary of

Page 25 Public Comments in Response to the GAPMS at issue in 1 this case. MS. DEBRIERE: We'll mark that as Exhibit 25. 3 (Thereupon, Plaintiff's Exhibit No. 25 was 4 5 marked for identification.) BY MS. DEBRIERE: 6 7 Who wrote this memo? Ο. I wrote it. 8 Α. Ο. Okay. Why? 10 So, at the direction of our general counsel's Α. 11 office, following the rule hearing on July 8th, we 12 decided to go ahead and do a written comment summary in 13 response to some of the written comments that we received. And also to summarize some of the verbal 14 15 comments that were provided during the -- during the 16 hearing. And -- and also because we did see Plaintiffs' 17 attorneys at the hearing. So we figured litigation was imminent. 18 19 So then what -- what was the purpose that this 20 document was supposed to serve? So we re -- did receive substantial written 21 2.2 comments, particularly from three clinical organizations. And -- which, of course, these documents 23 24 were not just sent to us, they were also publicly released and became publicly available. Because they 25

Page 26 make substantial claims about the validity of our GAPMS 1 2. memo, we needed to create an internal document that 3 would, of course, explain and -- any potential issues or ex -- respond to any criticisms that, of course, those 4 5 that weren't intimately familiar with the process might 6 be aware of. 7 0. And so the three organizations that you did 8 responses to, comments on, were Yale University, 9 Endocrine Society -- I'm sorry. There's four -- no, no, 10 no, three. Yale University, Endocrine Society and the 11 American Academy of Pediatrics. Is that correct? 12 A. That's correct. 13 0. Why did you pick those three? 14 So those are the three that sent us the A. 15 substantial comments that had particular criticisms 16 towards our GAPMS report. 17 Why didn't you respond to any of the other public comments that were provided or create a written 18 19 detailed response like you did with these three? 20 The other comments were usually very brief, A. 21 made very general statements. Some of them made 22 expletive-laden statements, because those comments didn't -- weren't looking at the legality of our rule. 23 It wasn't looking at the -- the credibility of the basis 24 for that rule. We didn't do written summaries of those 25

Page 27 1 comments. 2 O. Which one of the comments looked at the --3 criticized the legality of your role? Yale University's did. 4 A. 5 Okay. And then the Endocrine Society, and AAP 0. along with Yale also criticized the basis for your 6 7 decision; is that correct? 8 Their criticisms were more limited to the GAPMS A. 9 memo. 10 0. And they disagreed with that conclusion? 11 A. They disagreed with it. 12 Why was it sent to the experts? Q. Because we also wanted them to see the comments 13 A. that were submitted via these institutions. And we 14 15 wanted to make sure that our response were as complete 16 as possible. 17 Were you intending to release the com -- the --18 this report at some point? I quess, I'm still just not 19 understanding the use of the report. 20 A. So the re -- the use of the report was to have an internal memo for those involved in the GAPMS 21 22 process. And those, of course, would be involved in the 23 imminent litigation of what was said about our report and what our responses were. Now only a small handful 24 of us in the agency were intimately involved in the 25

305-376-8800

Page 28 1 development of the GAPMS memo. So we needed to share 2 that information with other agency staff. 3 So this report wasn't created to assess the validity or -- this report was not created for use --4 5 for AHCA's use in determining whether or not it should 6 adopt the rule? 7 **A**. That's correct. 8 Okay. Why not look at and respond to all 0. 9 comments that question the validity or credibility of 10 the GAPMS report? Because while a lot of comments hurled 11 12 criticisms at us, they weren't substantiated criticisms. 13 They just were saying we're wrong or --14 0. So that --15 A. -- things like that. Just very general 16 statements that didn't actually provide a -- a reasoned 17 case as to why we should not go forward with the rule, these comments did. 18 19 Okay. So -- okay. Was this document ever 20 intended to become public at some point? 21 **A**. No. 22 Is this the only document AHCA prepared 0. 23 summarizing or responding to public comment, provided in response to the adoption of 59G-1.050(7)? 24 That's the only document. 25 A.

Page 29

- Q. Including these, did any of the public -including the comments from AAP, Yale and the Endocrine
  Society, did any of the public comments submitted lead
  AHCA to reconsider the credentials of the consultants it
  chose to prepare and submit reports in support of the
  GAPMS memo?
  - A. They did not.
  - O. Why?

- A. None of the comments provided any reasoning or evidence that would force us to redetermine the decisions we'd already made.
- Q. But you did think that the comments, particularly from Yale, AAP and the Endocrine Society, were substantiated and -- and reasoned through?
- A. They -- Yale put together 47 pages, and they make some pretty sensationalist claims about our report. They published that report. They -- they did a press release around that report. We needed to go through and analyze it, to make sure that their claims were just sensationalist and nothing more.
- Q. Okay. Because you'd previously described them -- the -- the reason that you gave me for why you considered their comments and created a detailed summary report of them was because they were reasoned and substantiated, unlike the other public comments

Page 30 1 provided. 2 They provided some fact-based arguments, if 3 that's what you're meaning. But these were still sensationalist in nature. They were poorly-reasoned 4 5 arguments. What criteria did you use to determine whether 6 0. 7 they were poorly reasoned? 8 Just the standard critical thinking procedures A. 9 that you would apply to research and analysis. 10 Okay. So it's your position that the comments 11 provided by Yale, the Endocrine Society and AAP, were 12 poorly-reasoned criticisms of the GAPMS report? 13 A. That's my personal opinion, yes. 14 What's the Agency's opinion? 0. 15 A. The Agency's opinion was that they were flawed 16 arguments, and that they weren't sufficient to warrant 17 overturning the GAPMS report or decision to move forward with the rule promulgation. 18 19 And were you the only person who determined 20 whether the report -- the comments of Yale, the Endocrine Society and AAP, were comments that AHCA would 21 22 disregard in adopting the opinions set forth in GAPMS? 23 MR. PERKO: Object to form. THE WITNESS: I was the only author of that 24 document, but I was not the only person who read 25

```
Page 31
         those comments. As I said, we did mail copies to
1
         their experts and, of course, we had other internal
 2
         staff look and review the comments and the rebuttal.
 3
     BY MS. DEBRIERE:
 4
 5
              And what internal staff at AHCA agreed with
     your position about the organization's comments?
 6
7
              That'd have been my immediate supervisor,
8
     Devona Pickle.
9
         0.
              Anybody else?
10
         A.
              She was -- she -- she had reviewed them as well
11
     and reviewed my work.
12
         Q.
              Uh-huh.
13
         A.
              That was pretty much the extent of it. Then
14
     we, of course, presented our responses to leadership.
15
         0.
              And who's leadership?
16
              That would have been Secretary Marstiller and
17
     General Counsel Josefina Tamayo.
              Okay. And did they agree with what is
18
         0.
     contained in this report?
19
20
              They agreed with our findings.
         A.
              Okay. I understand that you were the only one
21
22
     who wrote the report. Did anybody make any edits in the
23
     report?
              As far as any edits, no. Nobody else worked on
24
     that document. We did get a suggestion from Dr. VanMol
25
```

Page 32 1 to include information about Western European countries, 2 in a response to Yale. That was it. 3 Okay. I'm sorry, Mr. Brackett. Say that 0. You asked Dr. VanMol to include --4 again. 5 No, Dr. VanMol said that we should mention A. he -- we should consider including information from the 6 7 Western European countries. 8 Okay. And so you had not previously thought 9 about that. That was Dr. VanMol's suggestion? 10 For this -- for the rebuttal, yes. We were, of A. 11 course, aware of it. But that was his suggestion to 12 make it more complete. 13 Okay. So taking each comment individually, 0. 14 starting with Yale, what was the basis for determining 15 whether it was poorly reasoned? 16 So the basis was that no other argument's 17 valid. What is the -- what is the basis for their 18 arguments? Do they make a case? Or when -- when you 19 apply scrutiny, which, in other words questioning, when 20 you start applying those standard analytical methods, do they hold up. And they didn't. We found that they were 21 22 making comparisons to drugs, et cetera, making analogies 23 that just didn't apply. 24 O. So the reason it was poorly reasoned was simply because they were making analogies that didn't apply? 25

Page 33 1 MR. PERKO: Object to form. 2 THE WITNESS: That's an example. 3 BY MS. DEBRIERE: Okay. Can you give me other examples? 4 0. 5 A. I can. But those are also explained in the --6 in the rebuttal. 7 When you say it's not valid criteria, what 0. 8 are -- valid reasoning, what makes something valid? 9 A. What would make something valid is that it's a 10 point, you -- you can't really take argument with it. 11 And it make -- would make you walk back from your 12 position, knowing that that's an argument that you 13 cannot overcome. In other words, it's well thought, it's logical, it's supported by evidence. 14 15 Q. So it's your position that nothing in the Yale 16 comment was supported by -- that the thrust of the Yale 17 comment was not supported by evidence? There was -- it could be explained that way. 18 A. 19 They provide some evidence for their arguments but their 20 arguments were nonapplicable. Their arguments danced around our main points. 21 22 Okay. What about the basis for determining Q. 23 that AAP's comment was poorly reasoned? A. The same basis. 24 Q. So they didn't have any evidence for their 25

Page 34 1 comments? A. Correct. 2 3 Okay. And they missed --A. Well, let me rephrase that. They did not have 4 5 what we'd consider credible evidence, to support their 6 arguments. 7 Okay. So what does it mean to be credible? 0. 8 Well, we do explain that in our GAPMS A. 9 memo. We explain that in our rebuttal. 10 And did the -- like the -- the Yale comment, 0. 11 did the AAP comment miss AHCA's point? 12 The AAP comm -- comment was obfuscating the 13 fact that they -- that there was no standard of care 14 available for these services. The AAP comment 15 frequently referred to one. There was no standard of 16 care available for these. 17 Q. So it's AHCA's position there is no standard of 18 care? 19 That's not our pos -- that's not our position. 20 That's just the reality of the situation. Okay. So what was the basis for determining 21 2.2 whether the Endocrine Society's comment was poorly reasoned? 23 A. Similar basis as to Yale's. There's was the 24 briefest of the three. 25

Page 35 1 Okay. So they didn't present evidence to 2 support their comment? 3 A. Correct. Q. Okay. And they --4 5 A. Or they didn't provide credible evidence to 6 support their comment. 7 And did they -- like the Yale report, did they 0. 8 miss the point that AHCA was trying to make? 9 A. I don't think they missed it. But their --10 their -- their responses didn't fis -- sufficiently --11 sufficiently refute that. 12 Okay. And what was the point that AHCA was 13 trying to make? 14 The point that we made was in our GAPMS, that the evidence was too low quality to constitute -- um, 15 16 alignment with GAPMS. 17 Was there anything in any of the three comments that AHCA did agree with? 18 Are we talking about, like, any last thing or 19 20 are we talking --21 0. Yeah. 22 A. That, of course, I think the -- probably the 23 only thing that we could agree on is, that kids who are having issues and having gender dysphoria are worthy of 24 receiving some help of some kind. 25

Page 36 1 Okay. That's the only thing that you could 2 agree on with them? I'd have to review their comments to 3 redetermine whether or not there's anything we agree --4 5 could agree on. But at -- at large, we are -- I think we do agree that kids who experience gender dysphoria do 6 7 need evidence-based treatment. We disagree on what we consider to be sufficiently evidence-based treatment. 8 9 Okay. So the purpose of the report was to 0. 10 review those comments and then summarize your opinion 11 about those comments, right? 12 I wouldn't say my opinion. I would say mostly 13 more my counter-arguments. 14 O. Okay. So then when you were preparing this 15 report, the point was to refute what Yale, the AAP and 16 the Endocrine Society were saying? 17 Just to point out the flaws of what they were A. 18 saying, and to, of course, pose counter-arguments, 19 correct. 20 Q. Okay. Why start from a position where the 21 point is to refute? 2.2 MR. PERKO: Object to form. 23 THE WITNESS: I'll defer to my previous testimony. They make comments. They use hyperbolic 24 language. This was all released nationally in the 25

800-726-7007 305-376-8800

Page 37 media. Internally, we needed to make sure of the 1 2 substance behind their statements, we needed to 3 analyze that to make sure that hey, is there something in there that would be a fatal flaw or 4 5 not. BY MS. DEBRIERE: 6 7 Well, analyzing whether something was in there 0. 8 that would either support or not support your conclusion 9 under GAPMS is different from starting from a position 10 where you're writing a report to refute what they're 11 saying; is that right? 12 MR. PERKO: Object to form. 13 THE WITNESS: I'm having trouble following what 14 you're saying. 15 BY MS. DEBRIERE: 16 Yeah. So your previous testimony was you wrote 17 this report to refute what the AAP, the Endocrine 18 Society and Yale were saying; is that correct? 19 Since they were making arguments and criticisms 20 towards our GAPMS, that were not well founded the -the -- yes, we were refuting their counter-arguments. 21 22 At what point did you determine that they were not well-found -- founded comments? 23 Shortly after I read them. 24 A. When you were reviewing them did you go and 25 0.

Page 38 1 look into any of the research that they cite? 2 A. I did. 3 At the time that you were reading the comments you did? 4 5 A. I did. Okay. So, when you say pretty shortly after 6 0. 7 reading them, what do you mean? 8 Well, after I read them. I mean, or -- and --A. 9 and as I was reading them, since Yale went 10 point-by-point, as you read something. And, of course, 11 you being an attorney, you start analyzing the language 12 as you read it. 13 O. Okay. So either you realize, like, oh, they have a 14 15 point there, or you shake your head and be, like, no, 16 they don't. 17 Okay. So after -- directly after -- once you finished reading the comments, you had decided that they 18 19 were wrong? 20 A. I had decided that they were -- yeah. That 21 they were flawed, yes. 22 Okay. Did anyone at AHCA disagree with the 23 contents of this report? You mean, anyone who was in -- who had read 24 it -- read it and received the information on it? 25

```
Page 39
1
         0.
              I mean, anyone.
 2
         A.
              Anyone? I can't speak to every employee. Not
     every employee was made aware of that document either.
 3
              Are you of -- aware of anyone at AHCA who
 4
         Q.
 5
     disagreed with this report?
              With the GAPMS memo or the comment summary?
 6
         A.
7
              Well, let's start with the comment summary.
         0.
8
              I'm not aware of any employee who disagreed
         A.
9
     with the comment summary.
10
              Are you aware of any employee who disagreed
         0.
11
     with the GAPMS?
12
         A.
              I'm aware of one.
13
         0.
              Who?
              Jeffrey English.
14
         A.
15
         0.
              Only Jeffrey English?
16
         A.
              He's the only one that I'm aware of.
17
              Okay. Did anybody within leadership direct you
         Q.
     to make changes to your summary, after you drafted it?
18
         A.
19
              No.
20
              Okay. So it's perfectly written as is? No one
         0.
21
     edited it?
22
              MR. PERKO: Object to form.
23
              THE WITNESS: It is -- it is purely my work
         product. So we got the one suggestion from
24
         Dr. VanMol, but I added that in myself.
25
```

```
Page 40
1
     BY MS. DEBRIERE:
 2
         Q. So what -- no one made any changes to this
 3
     document. It's just purely your work product?
         A. Yeah.
 4
 5
             Okay. Okay. So the General Counsel's office
         0.
 6
     never made any edits to this report?
7
             No, they did not.
         A.
8
              Okay. They directed you to create the report,
         0.
9
     but they did not tell you what content to put in it; is
10
     that correct?
11
             We were instructed to look at the comments,
12
     review them and provide analyses of them. Of course,
13
     that would be maintained internally.
14
         O. Okay. Other than the comment from Dr. VanMol,
15
     were there any other -- was there any other feedback
16
     from the experts?
17
         A.
             No.
             So did they tell you anything after they read
18
         0.
19
     the report?
20
         A.
             No.
21
         0.
              Okay. So you sent them the report, and then
22
     they didn't make any mention of it after that?
23
              MR. PERKO: Asked and answered.
              THE WITNESS: I'd already said that they
24
         didn't.
25
```

Page 41 1 BY MS. DEBRIERE: 2 O. Okay. Who did you send this document to before 3 finalizing? So we sent that to Dr's., VanMol, VanMeter, and 4 5 Grossman (phonetic). Okay. Did you send it to anyone internally to 6 7 AHCA, before finalizing? 8 Well, I mean, we did provide copies to 9 Secretary Marstiller, General Counsel. So they did have 10 it to review. 11 Q. Okay. And they provided you feedback to make 12 changes? 13 A. They did not request any changes. 14 Okay. And they being General Counsel's Office, 0. 15 but also AHCA leadership? 16 A. Correct. 17 Okay. Okay. So the GAPMS memo -- I'm sorry. Q. 18 The GAPMS regulation presumes that services either meet the GAPMS requirement or they do not. And if they do 19 20 not, then those services are experimental, correct? 21 That's what we determined, yes. 22 In the 2022 GAPMS process, you determined that Q. 23 the services listed in 59G-1.050 subpart (7) are experimental, correct? 24 That's what is written in the GAPMS memo, yes. 25 A.

Page 42 And, therefore, AHCA adopted the categorical 1 2 exclusion for the treatment of gender dysphoria from Medicaid coverage; is that correct? 3 That's correct. 4 A. 5 O. Okay. MS. DEBRIERE: So can I have the Errata sheet? 6 7 (Thereupon, Plaintiff's Exhibit No. 26 was marked for identification.) 8 BY MS. DEBRIERE: 10 So this is marked as Exhibit 26, it's the 11 Errata sheet that you sent to us yesterday. So, on this 12 Errata sheet, you're saying that there are potentially 13 situations where an individual can prove that the treatment -- the services listed at 59G-1.050(7) to 14 15 treat gender dysphoria can not be experimental; is that 16 correct? 17 No. That's not how that's to be -- to be Α. 18 interpreted. Okay. So I'm looking at this Errata sheet, and 19 20 it says that you can use the variance and waiver process -- "An individual can use the variance and 21 22 waiver process to have an individual determination as to whether one of the services listed at 59G-0 --23 1.050(7) -- subpart seven is not experimental to treat 24 their gender dysphoria." 25

Page 43 1 That text means that they are entitled to 2 review under the legal process. 3 Are there any circumstances in which that request would be granted? 4 5 We don't know. That'd be speculation. A. Well, if it was granted, then the person would 6 0. 7 have proven that the service was not experimental as to 8 them, correct? 9 In a very hypothetical situation, if a variance 10 is approved for coverage of these services, it would be 11 strictly on that individual basis and that individual's 12 basis alone. 13 But that individual would have to prove that 14 the treatment for gender dysphoria listed at 59G-1.050 15 subpart(7) was not experimental as to them, correct? 16 Hypothetically speaking, if it was to be 17 approved, they would have to satisfy proof, that it wouldn't be experimental, as to them. 18 19 So AHCA believes there are situations in which Ο. 20 the services listed at 59G-1.050 subpart(7) to treat 21 gender dysphoria can not be experimental? 2.2 MR. PERKO: Object to form. 23 THE WITNESS: That is not what we are saying 24 The variance of the process is a legal process because of -- of the Agency's rulemaking 25

Page 44 authorities. And then, of course, every agency can 1 allow for variances, no matter what the rule says, regardless of whether it applies to health care, 3 environment, business, commerce, et cetera. This is 4 5 a legal process. BY MS. DEBRIERE: 6 7 I understand that anybody can access the legal Q. 8 process. 9 Α. Uh-huh. 10 But under what situations would AHCA grant that Ο. 11 specific variance request? 12 MR. PERKO: Object to form. 13 THE WITNESS: We would be speculating. BY MS. DEBRIERE: 14 15 Ο. The individual would have to prove that the 16 services are not experimental as to them, correct? 17 MR. PERKO: Asked and answered. 18 THE WITNESS: The burden of proof is on the recipient. 19 20 BY MS. DEBRIERE: 21 To prove that the service is not experimental? Ο. 2.2 MR. PERKO: Objection to form. THE WITNESS: The burden of proof is on the 23 recipient. 24 2.5 BY MS. DEBRIERE:

Page 45

- Q. What do they have to prove?
- A. They have to prove your -- for -- they've -- they have to prove substantial hardship because of the -- of the rule. That's what the grounds under which a variance is granted.
- Q. Would they have to prove that the services are not experimental, as to them?
  - A. They would have to prove substantial hardship.
- Q. Substantial hardship to receive services that AHCA has determined are experimental?

MR. PERKO: Object to form.

THE WITNESS: The GAPMS memo is -- serves as the basis to say, that they're experimental and investigational. If -- if -- and if a recipient feels that -- that their -- that rule is causing them substantial hardship, they are welcome to try to request a variance and have it undergo the review process.

#### BY MS. DEBRIERE:

Q. I understand that an individual -- I understand that an in -- any individual can access the waiver -- the variance and waiver process. What I'm asking is, in order for AHCA to approve that variance request, what does the individual have to establish?

MR. PERKO: Object to form. Asked and

1

2.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

2.5

Page 46 answered. 1 BY MS. DEBRIERE: 3 Let's scratch that. Ο. Looking at the Erat -- the Errata sheet, you 4 5 say, add the line, that AHCA decides whether a -- a service is experimental as to the requester. 6 7 A. And --8 Is that the testimony? 0. 9 A. Yes. 10 Okay. So in order to have a variance approved, O. the individual has to -- AHCA decides whether a service 11 12 is experimental, as to the requester? 13 Α. It could be interpreted that way. 14 I'm trying to understand what AHCA's policy is, 15 as it relates to a request for a variance or waiver, for 16 someone who is seeking treatment -- seeking a service in 17 59G-1.050 subpart(7) to treat gender dysphoria. 18 Α. So --19 MR. PERKO: Object to form. 20 THE WITNESS: -- we previously did explain the variance review process. It's very individualized. 21 2.2 Because it's very individualized, we really can't speak to what we would exactly request because of 2.3 2.4 the individualized nature of the variance process. It would be speculation. 25

Page 47 BY MS. DEBRIERE: 1 2 O. So you cannot sit here today and tell me one example of an individual who would be granted a variance 3 from 59G-1.050 subpart(7)? 4 5 No, it's all hypotheticals. I'm not asking for a hypothetical. I'm asking 6 0. 7 for an example. Can you give me one example? MR. PERKO: Asked and answered. 8 9 THE WITNESS: Any examples we would give would 10 be hypothetical. 11 BY MS. DEBRIERE: 12 Mr. Brackett, you have written here that it is Q. 13 AHCA's position that when someone requests a variance or 14 waiver from this rule then it is AHCA's rule to 15 determine whether the service is experimental, as to the 16 requester. Is that correct? 17 Those are the words I wrote, yes. A. In what situations could AHCA decide whether a 18 Ο. 19 service is -- is not experimental as to the requester? 20 MR. PERKO: Object to form. 21 BY MS. DEBRIERE: 2.2 If you have decided that these service are O. 23 always experimental, they're either experimental or 24 they're not. 2.5 MR. PERKO: Object form.

```
Page 48
     BY MS. DEBRIERE:
 1
         O.
              Is that correct?
              I defer to the conclusions we drew -- drew in
 3
         Α.
     the GAPMS memo.
 4
 5
              The services are either experimental or they're
     not, correct? So -- excuse me. Under the GAPMS memo,
 6
7
     you determine that all the services are experimental,
8
     correct?
9
         A. When --
10
         Q. As to everyone?
11
         A. When used for those clinical indications,
12
     correct.
13
         Q. When used for the treatment of gender
14
     dysphoria?
15
         A. Correct.
16
              So all situations, where one of those services
17
     is being used to treat gender dysphoria, in all
     situations, the services are experimental, correct?
18
19
         A. Based on our GAPMS memo determination, yes.
20
         Q.
              Okay.
              MS. DEBRIERE: Okay. Let's -- let's take a
21
2.2
         five-minute break.
                                 Okay. This concludes Video
23
              THE VIDEOGRAPHER:
         One of the continued video-recorded deposition of
24
         Matthew Brackett. The time is 11:07 a.m.
25
```

Page 49 (Discussion held off the record.) 1 THE VIDEOGRAPHER: This is the beginning of 3 Video Two of the continued video-recorded deposition of Matthew Brackett. The time is 11:17 a.m. 4 5 BY MS. DEBRIERE: All right. Mr. Brackett, turning back to your 6 Errata sheet. It -- reviewing it yesterday, I noticed 7 that there are just a lot of places where you delete 8 9 entire lines, and then substitute a few words. And the 10 reason behind that is, because your position it's a more 11 accurate description of agency policy. Um, how did you 12 learn about those more accurate descriptions of agency 13 policy? Those came from our General Counsel's Office. 14 A. 15 0. Um, so did you review your deposition with the 16 General's Counsel's Office, and they directed you to 17 include these in that Errata sheet? Yes. And (inaudible) outside counsel to make 18 A. sure it was as accurate as possible. 19 20 Is outside counsel aware of accurate -- more 0. accurate agency policy? 21 2.2 A. Yes. 23 0. How? Via our General Counsel's Office. 24 A. So General Counsel's Office gave outside 25 0.

Page 50 1 counsel a more accurate description of agency policy, 2 and then outside counsel directed you to fill out this 3 Errata sheet? It was a team effort, yes. 4 A. 5 Are these policies kept anywhere? 0. A. I mean, these policies are -- these statements 6 are more in line -- aligned with the statutes, as 7 8 written, when it comes to requesting variances and rulemaking. 9 Q. Okay. But your reason is that you are 10 11 providing a more accurate description of agency policy. 12 So they're not policies that are written; is that 13 correct? 14 If you're talking about promulgated policies 15 that go through the rulemaking process --16 I'm not. I'm talking about internal policies 17 or formally-adopted policies. This would be more reflective of -- of our 18 A. internal processes, yes. 19 20 Q. Okay. And are those internal processes written 21 anywhere? 2.2 A. Can't speak to that at this time. Okay. So you don't know? 23 0. Don't know. 24 A. Okay. So can you find that out for me, please? 25 0.

Page 51

- 1 A. We can check to see if there is a -- if the
  2 General Counsel's Office has a written process for
  3 variances.
  - Q. As to the treatment of gender dysphoria?
- A. As to the treatment of gender dysphoria?
  - Q. Uh-huh.

4

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

23

24

25

- A. There isn't one.
- Q. Okay. How did you learn that your initial responses were not accurate?
  - A. We just reviewed the transcript.
- Q. But as it stands, what's in the Errata sheet is your testimony, correct?
  - A. This is my testimony, correct.
- Q. Okay. Would you agree that there are individuals for whom their gender dysphoria cannot be resolved with only psychotherapy?
- A. That is a statement that, of course, is going to be made by individual clinicians. That's not -- that's not a statement -- the Agency's not in a position to discuss the effectiveness of medical treatments, when it comes down to individuals such as -- such as you're describing.
- Q. Okay. But the agency isn't in a position -- is in a position to determine whether or not services are experimental, as to the provision to Medicaid

Page 52 (inaudible)? 1 That's a different question. That's a Α. 3 different scene -- scenario. Okay. So in what scenario -- I'm sorry. 4 0. So 5 then would the --So can you please repeat that question? 6 7 Yes. Would you agree that there are Ο. individuals, for whom their gender dysphoria cannot be 8 resolved with only psychotherapy? 10 So just because one treatment may not 11 necessarily be effective, doesn't mean that a treatment 12 that we've deemed to be experimental and investigational 13 is going to be effective. 14 Okay. So it is not the Agency's position that individuals who are suffering from gender dysphoria, the 15 16 only method of treatment that is appropriate is 17 psychotherapy? 18 We can't speak to that because that's kind of 19 an absolute statement. We do deem psychotherapy as 20 being an appropriate treatment. But in regards to the 21 other treatments, such as those discussed in the GAPMS 2.2 memo, those are experimental/investigational. Okay. I -- but that's not quite my question, 23 Ο. 24 I mean, my question is, is it the Agency's position that there are medical circumstances, in which 25

Page 53 a Medicaid beneficiary who's suffering from gender 1 2. dysphoria needs treatment other than psychotherapy? MR. PERKO: Object to form. 3 THE WITNESS: We're talking only about 4 5 psychotherapy, correct? BY MS. DEBRIERE: 6 7 Q. Yes. We could probably say yes. 8 Α. 9 Q. Okay. 10 MS. DEBRIERE: Are there any other questions 11 that I've missed, Simone? 12 Okay. All right. That's it for Plaintiff's 13 side. 14 MR. PERKO: I got no questions. 15 THE VIDEOGRAPHER: Anybody via Zoom? 16 MS. DEBRIERE: We're good, but thank you. 17 THE VIDEOGRAPHER: Okay. This concludes the video-recorded deposition of Matthew Brackett. 18 The 19 time is 11:23 a.m. (Discussion held off the record.) 20 21 COURT REPORTER: Is anyone requesting a copy of 2.2 this deposition at this time? 23 MS. DEBRIERE: Yes, we will. 2.4 MR. PERKO: And we will take a copy. 2.5 (Discussion held off the record.)

800-726-7007 305-376-8800

```
Page 54
               MS. DEBRIERE: Ms. Mercer, can you send it to
 1
 2
         the person who initially organized your services?
               (Discussion held off the record.)
 3
               COURT REPORTER: Bill it to Jennifer Altman?
 4
 5
               MS. DEBRIERE: Yes, please.
               (Deposition concluded at 11:23 a.m.)
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

Page 55 1 CERTIFICATE OF OATH 2 STATE OF FLORIDA: 3 4 COUNTY OF DUVAL: 5 6 I, LAWANDA MERCER, Florida Professional Reporter, 7 Notary Public, State of Florida, do hereby certify that 8 MATTHEW BRACKETT personally appeared before me on 11th day of March, 2023, and was duly sworn and produced 9 Florida driver's license as identification. 10 11 Signed this 23rd day of MARCH, 2023. 12 13 14 15 16 17 LAWANDA MERCER Florida Professional Reporter Notary Public, State of Florida 18 My Commission No.: HH 285925 Expires: July 25th, 2026 19 20 21 22 23 24 25

Page 56 CERTIFICATE OF REPORTER 1 2 STATE OF FLORIDA: COUNTY OF DUVAL: 3 4 5 I, LAWANDA MERCER, Florida Professional Reporter, Notary Public, State of Florida, certify that I was 6 7 authorized to and did stenographically report the deposition of MATTHEW BRACKETT; that a review of the 8 9 transcript was requested; and that the foregoing transcript, pages 5 through 53, is a true and accurate 10 record of my stenographic notes. 11 12 I further certify that I am not a relative, employee, or attorney, or counsel of any of the parties, 13 14 nor am I a relative or employee of any of the parties' 15 attorneys or counsel connected with the action, nor am I financially interested in the action. 16 17 DATED this 23rd day of March, 2023. 18 19 20 21 22 LAWANDA MERCER Florida Professional Reporter 23

24

25

CASE NO: 4:22-CV-00325-RH-MAF  DATE: MARCH 8TH, 2023  DEPONENT: MATTHEW BRACKETT			Page
IN RE: AUGUST DEKKER ET AL. VS. JASON WEIDA, ET AL., CASE NO: 4:22-CV-00325-RH-MAF DATE: MARCH 8TH, 2023 DEPONENT: MATTHEW BRACKETT			ERRATA SHEET
WEIDA, ET AL.,  CASE NO: 4:22-CV-00325-RH-MAF  DATE: MARCH 8TH, 2023	DO	NOT WRITE OF	N TRANSCRIPT-ENTER CHANGES HERE
CASE NO: 4:22-CV-00325-RH-MAF  DATE: MARCH 8TH, 2023  DEPONENT: MATTHEW BRACKETT		IN RE:	AUGUST DEKKER ET AL. VS. JASON
DATE: MARCH 8TH, 2023 DEPONENT: MATTHEW BRACKETT	WEIDA, ET	Г AL.,	
DEPONENT: MATTHEW BRACKETT		CASE NO:	4:22-CV-00325-RH-MAF
		DATE:	MARCH 8TH, 2023
PAGE NO. LINE NO. CORRECTION & REASON		DEPONENT: I	MATTHEW BRACKETT
	PAGE NO.	LINE NO. CO	ORRECTION & REASON
Under penalties of perjury, I declare that I have read	 Under new	alties of p	eriury I declare that I have re
the foregoing document and that the facts stated in i			
	are true	, <b>"</b>	
are true."			
are true."			

Page 58 March 23rd, 2023 1 MATTHEW BRACKETT 2 C/o Gary Vergil Perko Gperko@holtzmanvogel.com 3 4 In Re: March 8th, 2023, Deposition of MATTHEW BRACKETT 5 Job# 5801255 6 Dear MATTHEW BRACKETT: 7 This letter is to advise that the transcript for the above-referenced deposition has been completed and is available for review. Please read the transcript, make 8 any changes and sign the errata sheet provided, then email 9 completed errata to transcripts-fl@veritext.com and to all ordering parties. It is suggested that the review of this transcript 10 be completed within 30 days of your receipt of this 11 letter, as considered reasonable under Federal Rules\*; however, there is no Florida Statute to this regard. 12 The original of this transcript has been forwarded to the ordering party and your errata, once received, 13 will be forwarded to all ordering parties for inclusion 14 in the transcript. 15 Sincerely, 16 17 Veritext Legal Solutions 18 cc: Katherine Jean Ann DeBriere, Esquire Gary Vergil Perko, Esquire 19 Waiver: 2.0 \_\_\_\_\_, hereby waive the reading and signing of my deposition transcript. 21 22 Deponent Signature Date 23 \*Federal Civil Procedure Rule 30(e)/Florida Civil Procedure Rule 1.310(e) 2.4 2.5

[**& - aetna**] Page 59

	I		1
&	58:5	5	36:15 37:17
<b>&amp;</b> 57:6	<b>2026</b> 55:19	<b>5</b> 3:3,12 56:10	<b>aap's</b> 33:23
0	<b>20th</b> 13:21	<b>500</b> 2:8	above 58:7
-	20:10	<b>53</b> 56:10	absolute 52:19
0 42:23	<b>21st</b> 17:13 18:12	<b>55</b> 3:4	absolutely 15:9
<b>00325</b> 1:5 4:6	18:16	<b>56</b> 3:5	20:7
57:4	<b>22890</b> 55:16	<b>57</b> 3:6	academy 26:11
1	56:21	<b>58</b> 3:7	access 44:7
<b>1.050</b> 28:24	<b>22nd</b> 17:4	<b>5801255</b> 58:5	45:21
41:23 42:14,24	<b>23rd</b> 55:11	<b>59g</b> 28:24 41:23	accordance 9:2
43:14,20 46:17	56:18 58:1	42:14,23 43:14	accurate 49:11
47:4	<b>24</b> 3:12 5:16,17	43:20 46:17	49:12,19,20,21
<b>1.310</b> 58:24	<b>25</b> 3:13,13 25:3	47:4	50:1,11 51:9
<b>10:00</b> 1:10	25:4	6	56:10
<b>10:09</b> 4:9	<b>25th</b> 55:19		action 56:15,16
<b>119</b> 2:8	<b>26</b> 3:15 42:7,10	<b>6th</b> 5:11	actually 13:11
<b>11:07</b> 48:25	<b>27</b> 10:7,12	7	23:18 28:16
<b>11:17</b> 49:4	<b>2727</b> 4:7	<b>7</b> 28:24 41:23	<b>ad</b> 11:20 12:6
<b>11:23</b> 53:19	<b>285925</b> 55:18	42:14,24 43:15	<b>add</b> 46:5
54:6	3	43:20 46:17	added 14:6
<b>11:44</b> 1:10	<b>30</b> 58:10,23	47:4	39:25
<b>11th</b> 55:9	<b>32205-9330</b> 2:4	8	adolescence
<b>19</b> 13:19 18:24	<b>32301-1591</b> 2:8	850-391-0502	20:13
2	352-496-5419		adolescent
<b>2</b> 6:7	2:4,4	2:9,9 <b>8th</b> 1:0 4:8 5:15	24:21
	<b>3900</b> 2:3	8th 1:9 4:8 5:15 10:18 25:11	adopt 28:6
<b>2017</b> 16:9,13,19 16:23,24 17:13	<b>3rd</b> 13:21		adopted 42:1
18:12 24:14	4	57:4 58:5	50:17
<b>2018</b> 23:21		a	adopting 30:22
	<b>4</b> 15:11,16 23:2	<b>a.m.</b> 1:10,10 4:9	adoption 18:8
<b>2022</b> 13:21,21	42 3:15	48:25 49:4	28:24
17:4,11,20	<b>47</b> 29:15	53:19 54:6	advanced 18:17
20:10 41:22	<b>4:22</b> 1:5 4:6	<b>aap</b> 27:5 29:2	advise 58:7
<b>2023</b> 1:9 4:9	57:4	29:13 30:11,21	aetna 24:5
5:11 55:9,11		34:11,12,14	
56:18 57:4 58:1			

[affirm - auto] Page 60

affirm 5:1	<b>ahca's</b> 10:19	antagonist	<b>ashley</b> 19:16,19
agency 4:22	23:7,17 28:5	24:21	asked 32:4
15:5 16:18	34:11,17 46:14	anybody 31:9	40:23 44:17
20:15 22:9,11	47:13,14	31:22 39:17	45:25 47:8
22:14 27:25	ahca.myflorid	44:7 53:15	asking 9:10
28:2 44:1 49:11	7:9	apologize 17:11	18:25 45:22
49:12,21 50:1	<b>ahead</b> 25:12	appear 19:3	47:6,6
50:11 51:23	<b>al</b> 1:3,6 2:7 4:5	appeared 55:8	assess 28:3
<b>agency's</b> 30:14	4:6 57:3,3	appearing 2:6	assistance 23:5
30:15 43:25	<b>align</b> 17:25	2:10	23:7
51:19 52:14,24	aligned 50:7	applies 44:3	<b>assume</b> 10:12
ago 15:4	alignment 35:16	<b>apply</b> 16:21,22	attorney 6:20
<b>agree</b> 6:10	<b>allow</b> 44:2	24:9,22 30:9	38:11 56:13
31:18 35:18,23	altman 2:13	32:19,23,25	attorneys 25:17
36:2,4,5,6 51:14	4:20 54:4	applying 32:20	56:15
52:7	american 26:11	appreciate 7:13	<b>august</b> 1:3 4:5
agreed 3:18	<b>analog</b> 15:18	appropriate	17:13 18:12,16
31:5,20	20:25 22:25	52:16,20	57:3
<b>ah</b> 16:16	analogies 32:22	approve 45:23	<b>auth</b> 9:18
<b>ahca</b> 3:13 7:5,8	32:25	approved 8:25	author 30:24
8:24 11:10,22	<b>analogs</b> 20:1,12	13:2 43:10,17	authorities 44:1
13:20 15:20	analyses 40:12	46:10	authorization
16:10,16 17:5	analysis 30:9	<b>april</b> 13:21	8:2,9,19,24 9:13
18:6,15,24 19:6	analyst 14:3	20:10	9:16,18 10:14
20:2,11,17,19	analytical 32:20	argument 33:10	10:25 13:15
20:21,23 21:3	analyze 29:19	33:12	14:23
22:21,23 24:20	37:3	argument's	authorizations
24:25 28:22	analyzing 37:7	32:16	9:11,21
29:4 30:21 31:5	38:11	arguments 30:2	authorized 56:7
35:8,12,18	andrew 2:12	30:5,16 32:18	<b>auto</b> 7:12,15,19
38:22 39:4 41:7	4:22	33:19,20,20	7:25 8:2,10,15
41:15 42:1	<b>ann</b> 2:2 58:18	34:6 36:13,18	8:19 9:8,9,10,13
43:19 44:10	<b>answer</b> 22:19	37:19,21	9:18 10:1,3,4,6
45:10,23 46:5	answered 40:23	arlene 17:5	10:7,8,14 12:20
46:11 47:18	44:17 46:1 47:8		

#### [automatic - comments]

Page 61

automatic 9:14	<b>bill</b> 54:4	<b>ccm</b> 13:23 14:9	29:19
10:4	<b>bit</b> 5:24 6:4	cd 17:2	clarification 7:7
automatically	brackett 1:8 3:2	certificate 3:4,5	clear 16:5
7:17 9:15	4:4 5:6,11 15:16	55:1 56:1	clinical 8:9,18
available 15:8	32:3 47:12	<b>certify</b> 55:7 56:6	9:25 10:2,15
23:17,24 25:25	48:25 49:4,6	56:12	12:21 13:4
34:14,16 58:8	53:18 55:8 56:8	cetera 32:22	25:22 48:11
aware 26:6	57:5,25 58:2,5,6	44:4	clinicians 51:18
32:11 39:3,4,8	<b>break</b> 48:22	chain 22:8	<b>clo</b> 15:1
39:10,12,16	<b>brief</b> 26:20	challenge 17:22	<b>cms</b> 24:17,18,23
49:20	briefest 34:25	18:1	<b>code</b> 17:6,12,16
b	<b>burden</b> 44:18	<b>change</b> 13:23,25	18:7
<b>b</b> 10:11 17:2,6	44:23	14:4,9 16:23,24	<b>coded</b> 17:1,7
17:16 18:7	bureau 14:25	18:2,4,9,15,22	<b>codes</b> 11:25
back 6:8 12:15	business 44:4	18:25 19:7	14:1 16:10,17
12:18 13:7,21	c	changes 17:19	16:20 17:24
16:9 19:24	<b>c</b> 2:1 4:1 7:8	17:25 39:18	<b>com</b> 27:17
33:11 49:6	58:2	40:2 41:12,13	<b>comes</b> 50:8
<b>based</b> 30:2 36:7	calls 11:17	57:2 58:8	51:21
36:8 48:19	care 23:8,9,12	check 51:1	<b>comm</b> 34:12
<b>basically</b> 11:20	23:13 24:12	chelsea 2:14	comment 25:12
basis 7:15 9:2	34:13,16,18	4:21	28:23 32:13
11:20 14:5	44:3	children's 24:11	33:16,17,23
26:24 27:6	case 1:5 3:14	24:15	34:10,11,12,14
32:14,16,17	4:6 8:23 9:1,1	<b>chose</b> 29:5	34:22 35:2,6
33:22,24 34:21	25:2 28:17	<b>chriss</b> 2:2 4:16	39:6,7,9 40:14
34:24 43:11,12	32:18 57:4	4:16	comments 3:13
45:13	cases 13:17	circumstances	25:1,13,15,22
beginning 49:2	categorical 18:8	43:3 52:25	26:8,15,18,20
behalf 2:6,10	42:1	<b>cite</b> 38:1	26:22 27:1,2,13
believe 7:24	catherine 2:14	civil 58:23,23	28:9,11,18 29:2
12:17	4:21	<b>claim</b> 11:11,23	29:3,9,12,23,25
<b>believes</b> 43:19		claims 10:20,23	30:10,20,21
	causing 45:15	12:3 13:7,17	31:1,3,6 34:1
<b>beneficiary</b> 7:15 8:17 53:1	cc 58:18	14:3 26:1 29:16	35:17 36:3,10

Veritext Legal Solutions

800-726-7007 305-376-8800

#### [comments - dated]

36:11,24 37:23	contained 6:15	53:5	created 28:3,4
38:3,18 40:11	31:19	correction 57:6	29:23
commerce 44:4	contains 6:11	counsel 3:19	credentials 29:4
commission	7:2	4:12,14,16,18	credibility
55:18	content 40:9	4:20 5:12 31:17	26:24 28:9
compare 9:7	contents 38:23	41:9 49:18,20	credible 34:5,7
comparisons	continue 20:18	50:1,2 56:13,15	35:5
32:22	continued 4:3	counsel's 25:10	criteria 6:7,15
complete 21:25	48:24 49:3	40:5 41:14	7:3 8:25 9:4,18
27:15 32:12	contract 23:15	49:14,16,24,25	11:22 14:22
completed 58:7	23:16,19,23	51:2	15:1,7,18,20,24
58:9,10	24:13,17	counter 36:13	16:5 22:22,25
computer 9:20	contracts 23:24	36:18 37:21	24:19 30:6 33:7
concluded 54:6	24:1	countries 32:1,7	criteria.shtml.
concludes 48:23	<b>control</b> 13:23,25	county 55:4	7:10
53:17	14:4,9 18:2,4	56:3	critical 30:8
conclusion	<b>copies</b> 31:1 41:8	<b>course</b> 9:1,21	criticisms 26:4
27:10 37:8	<b>copy</b> 5:12 14:8	10:4 11:24 15:3	26:15 27:8
conclusions	15:17 53:21,24	22:24 25:23	28:12,12 30:12
48:3	<b>correct</b> 6:6 9:14	26:3,4 27:22	37:19
condition 10:11	11:8,9,15 12:23	31:2,14 32:11	criticized 27:3,6
10:12	13:3 15:21,23	35:22 36:18	currently 16:2,8
connected 56:15	17:3,13,14,17	38:10 40:12	<b>cv</b> 1:5 4:6 57:4
consequence	17:18 18:13	44:1 51:17	d
12:9	23:3,6,8,10,13	<b>court</b> 1:1 4:9,13	<b>d</b> 3:1 4:1
consequences	23:17 24:12,23	4:24 5:5 6:20,24	<b>danced</b> 33:20
12:12	26:11,12 27:7	53:21 54:4	database 17:1
consider 32:6	28:7 34:2 35:3	coverage 10:16	date 1:9 4:8
34:5 36:8	36:19 37:18	12:22 42:3	16:12 18:10,11
considered	40:10 41:16,20	43:10	18:14,14,16,18
29:23 58:11	41:24 42:3,4,16	<b>covered</b> 13:1,3	18:19 57:4,25
constitute 35:15	43:8,15 44:16	<b>cpt</b> 14:1	58:22
consultants	47:16 48:2,6,8	<b>create</b> 14:3 26:2	<b>dated</b> 13:20
29:4	48:12,15,18	26:18 40:8	20:10 56:18
	50:13 51:12,13		20.10 20.10

[day - dr's] Page 63

1 77 0 11	16.41 7.22	40.10	1. 1. 27.10
day 55:9,11	definitely 7:23	48:19	disagreed 27:10
56:18	<b>dekker</b> 1:3 4:5	determinations	27:11 39:5,8,10
days 58:10	57:3	22:22,23	discuss 51:20
dear 58:6	<b>delay</b> 20:1,12	determine 8:24	discussed 52:21
debriere 2:2,5	delete 49:8	11:23 12:2	discussing
3:3 4:14,14,19	delivered 12:3	21:25 30:6	24:20
5:10,19 6:1,3,22	<b>denial</b> 7:16,20	37:22 47:15	discussion 49:1
6:22,25 7:1	8:1,4	48:7 51:24	53:20,25 54:3
14:14,16,19,20	denied 7:14	determined	dispensed 13:14
19:18 20:7,8	8:10,19 9:8	30:19 41:21,22	dispenses 12:11
25:3,6 31:4 33:3	10:14 12:20	45:10	dispensing
37:6,15 40:1	department	determining	12:15
41:1 42:6,9 44:6	24:15	28:5 32:14	disregard 30:22
44:14,20,25	deponent 3:19	33:22 34:21	district 1:1,1
45:19 46:2 47:1	57:5 58:22	development	division 1:2
47:11,21 48:1	deposition 1:8	28:1	document 5:20
48:21 49:5 53:6	3:5,20 4:4,7	devona 31:8	6:15 14:11
53:10,16,23	5:14 6:4 48:24	diagnosis 11:25	20:12,14 25:20
54:1,5 58:18	49:3,15 53:18	20:16	26:2 28:19,22
decide 47:18	53:22 54:6 56:8	<b>die</b> 14:21	28:25 30:25
decided 25:12	58:5,7,21	different 37:9	31:25 39:3 40:3
38:18,20 47:22	<b>depot</b> 10:9,11	52:2,3	41:2 57:22
<b>decides</b> 46:5,11	12:19	<b>direct</b> 3:3 5:9	documented
decision 27:7	described 29:21	16:10 17:5 18:6	21:10 22:16
30:17	describing	18:11,15 39:17	documents
decisions 21:9	51:22	directed 16:18	25:23
22:16 29:11	description 3:11	17:12 18:3 40:8	<b>doing</b> 9:24
declare 57:22	49:11 50:1,11	49:16 50:2	11:21
<b>deem</b> 52:19	descriptions	directing 18:21	<b>dollars</b> 11:5,7
<b>deemed</b> 52:12	49:12	19:6	12:14
defendant 2:10	detailed 26:19	direction 25:10	<b>dr</b> 31:25 32:4,5
defendants 1:7	29:23	directly 38:17	32:9 39:25
4:18	determination	disagree 36:7	40:14
<b>defer</b> 36:23 48:3	15:5 20:3,17,21	38:22	<b>dr's</b> 41:4
	20:23 42:22		

#### [drafted - explanation]

drafted 39:18	earlier 15:10	enter 57:2	exchanges
drew 48:3,3	16:6	entire 49:9	13:20
drive 4:7	<b>edited</b> 39:21	entitled 43:1	excluding 23:12
<b>driver's</b> 55:10	edits 31:22,24	environment	exclusion 17:22
<b>drug</b> 6:7,14,16	40:6	44:4	18:1,8 42:2
7:3,9,9,14,25	<b>effect</b> 18:9,10	<b>epsdt</b> 10:16	excuse 48:6
8:7,8 9:4 12:5,7	effective 52:11	12:22 13:1,3	exhaustive 6:11
12:16 13:1,2,14	52:13	equals 18:7	6:14 7:3 15:12
15:7 16:5	effectiveness	<b>erat</b> 46:4	16:3,7,8
<b>drugs</b> 10:24	51:20	<b>errata</b> 3:6,15	<b>exhibit</b> 3:12,13
11:15 12:11	effort 50:4	42:6,11,12,19	3:15 5:16,17
13:6 16:21	either 16:21	46:4 49:7,17	13:19 15:11,16
32:22	37:8 38:14 39:3	50:3 51:11 57:1	18:24 23:2 25:3
<b>due</b> 20:15	41:18 47:23	58:8,9,13	25:4 42:7,10
<b>duly</b> 5:7 55:9	48:5	<b>esquire</b> 2:2,2,7	exhibits 3:9
<b>dunn</b> 2:14 4:21	elicia 16:15	2:12,13,13,14	<b>experience</b> 36:6
duval 55:4 56:3	19:23,24 20:10	2:14 58:18,18	experimental
dysphoria 10:13	23:4	establish 45:24	41:20,24 42:15
14:22 20:2,13	elliott 17:5	et 1:3,6 2:7 4:5	42:24 43:7,15
20:25 22:25	<b>email</b> 58:8	4:5 32:22 44:4	43:18,21 44:16
24:22 35:24	employed 22:8	57:3,3	44:21 45:7,10
36:6 42:2,15,25	22:10,12	european 32:1,7	45:13 46:6,12
43:14,21 46:17	employee 21:13	evaluate 12:2	47:15,19,23,23
48:14,17 51:4,5	21:14 39:2,3,8	evidence 29:10	48:5,7,18 51:25
51:15 52:8,15	39:10 56:13,14	33:14,17,19,25	52:12,22
53:2	employees	34:5 35:1,5,15	experts 27:12
e	21:17	36:7,8	31:2 40:16
e 2:1,1 3:1 4:1,1	endocrine 26:9	<b>ex</b> 26:4	expires 55:19
13:20 14:10	26:10 27:5 29:2	exactly 46:23	explain 26:3
15:22 16:9 17:8	29:13 30:11,21	<b>examination</b> 3:3	34:8,9 46:20
18:21,22,24	34:22 36:16	5:9	explained 33:5
19:4,5,11,19,20	37:17	example 33:2	33:18
19:21,22,24	<b>english</b> 39:14,15	47:3,7,7	explanation
20:9 22:8 58:23	<b>ensure</b> 11:5,6	examples 33:4	7:13
58:24		47:9	

#### [expletive - granted]

expletive 26:22 extent 31:13	fis 35:10 five 48:22 fl 58:9	<b>found</b> 32:21 37:23 <b>founded</b> 37:20	53:1 genders 16:22 general 25:10
<del>-</del>			
fill 50:2 final 20:3,17 finalizing 41:3,7 financially 56:16 find 12:5,7 14:14,15,16 50:25 findings 31:20 finished 38:18 first 5:7,14 7:12 17:10 23:18	form 30:23 33:1 36:22 37:12 39:22 43:22 44:12,22 45:11 45:25 46:19 47:20,25 53:3 formally 50:17 forth 30:22 forward 28:17 30:17 forwarded 58:12,13	gary 2:7 4:18 6:1 14:14 58:2 58:18 gender 10:13 14:21 16:10,17 16:20 17:6,12 17:16 18:7 20:2 20:13,25 22:25 24:22 35:24 36:6 42:2,15,25 43:14,21 46:17 48:13,17 51:4,5 51:15 52:8,15	25:12 28:17 29:18 37:25 50:15 goes 8:15 going 5:15 12:18 22:24 51:17 52:13 good 53:16 gperko 2:9 58:3 grant 44:10 granted 43:4,6 45:5 47:3

[great - june] Page 66

great 10:5	<b>http</b> 7:9	32:6	intending 27:17
grossman 41:5	huh 15:13,23	inclusion 58:13	interested 56:16
	16:14 17:23	index 3:9	internal 14:21
grounds 45:4			
guess 9:9 27:18	23:20,22 31:12	indications	15:14,20 20:11
guidelines 9:3	44:9 51:6	48:11	22:24 26:2
h	humana 24:4,5	individual	27:21 31:2,5
<b>h</b> 7:8	humans 11:19	42:13,21,22	50:16,19,20
hand 4:25 5:16	hurled 28:11	43:11,13 44:15	internally 37:1
handful 27:24	hyperbolic	45:20,21,24	40:13 41:6
happen 13:16	36:24	46:11 47:3	interpreted
hard 17:6	<b>hyperlink</b> 6:6	51:18	20:20 42:18
hardship 45:3,8	<b>hypo</b> 12:18	individual's	46:13
45:9,16	hypothetical	43:11	intimately 26:5
head 24:3 38:15	10:6 43:9 47:6	individualized	27:25
health 2:3 24:15	47:10	46:21,22,24	introduce 4:12
44:3	hypothetically	individually	investigational
	43:16	32:13	45:14 52:12,22
hearing 20:15	hypotheticals	individuals	involved 27:21
25:11,16,17	47:5	51:15,21 52:8	27:22,25
<b>held</b> 4:7 49:1	i	52:15	issue 3:14 25:1
53:20,25 54:3	identification	information	issues 26:3
help 35:25		13:9,10,12 28:2	35:24
helpful 17:8	5:18 25:5 42:8	32:1,6 38:25	i
hey 37:3	55:10	initial 51:8	J '11 2.4
hh 55:18	imagine 10:10	initially 54:2	jacksonville 2:4
historic 22:5	immediate 31:7	instance 8:6	<b>jason</b> 1:6 4:5
historical 23:24	imminent 25:18	12:25	57:3
history 12:1	27:23	institutions	jean 2:2 58:18
<b>hoc</b> 11:20 12:6	implement 18:8	27:14	<b>jeffrey</b> 39:14,15
<b>hold</b> 15:16	inaudible 13:8	instructed	jennifer 2:13
32:21	14:23 17:4		4:20 54:4
holtzman 2:7	49:18 52:1	20:18 40:11	<b>job</b> 58:5
holtzmanvoge	include 24:7	integrity 10:19	josefina 31:17
2:9 58:3	32:1,4 49:17	intended 18:9	<b>july</b> 25:11 55:19
hormone 20:14	including 4:20	28:20	<b>june</b> 13:21 17:4
	24:11 29:1,2		17:11
	I .	ral Calutions	1

[justice - marked] Page 67

	1_		
justice 2:3	learn 7:18 49:12	looked 27:2	<b>main</b> 33:21
k	51:8	<b>looking</b> 10:6,7	maintained
katherine 2:2	legal 43:2,24	13:21 20:9	40:13
58:18	44:5,7 58:17	26:23,24 42:19	maintenance
<b>katy</b> 4:14 6:22	legality 26:23	46:4	14:1
keep 21:17	27:3	<b>lot</b> 28:11 49:8	<b>make</b> 14:2
kelly 22:6	<b>letter</b> 3:7 58:7	low 35:15	17:25 18:15,22
kept 21:14,20	58:11	<b>lupron</b> 10:9,10	18:25 19:6 26:1
50:5	license 55:10	12:19 20:16	27:15 29:16,19
kicked 8:1	limited 27:8	m	31:22 32:12,18
kids 35:23 36:6	line 4:19 22:24	<b>made</b> 15:4	33:9,11,11 35:8
kind 35:25	46:5 50:7 57:6	16:23,24 17:19	35:13 36:24
52:18	<b>lines</b> 49:9	20:3,18,20	37:1,3 39:18
king 16:15	<b>link</b> 7:12	26:21,21 29:11	40:22 41:11
20:10	linked 10:8	35:14 39:3 40:2	49:18 58:8
<b>know</b> 13:11	<b>list</b> 6:11,14,16	40:6 51:18	makes 33:8
14:11 19:13	7:3 9:8,10 10:6	maf 1:5 4:6 57:4	making 20:23
	10:7,8,11 15:12		22:21,23 32:22
21:3,7,8 43:5	16:2,7 21:5 22:1	magellan 9:22	32:22,25 37:19
50:23,24	<b>listed</b> 10:11	9:24 13:20 14:2	<b>male</b> 16:21
knowing 33:12	41:23 42:14,23	14:4,22 15:21	managed 23:5,7
l	43:14,20	16:15 17:5 18:3	23:8,9,12 24:12
<b>1</b> 3:17	litigation 25:17	18:5,7,15,17,21	<b>manual</b> 9:9,11
laden 26:22	27:23	18:25 19:6,23	9:13
language 17:7	little 5:24 6:4	19:24 20:20,22	manually 9:22
20:6 36:25	logical 33:14	20:24	9:25
38:11	long 23:12	mahan 4:7	<b>march</b> 1:9 4:8
<b>large</b> 36:5	longer 15:5	mail 13:20	5:11 55:9,11
lawanda 1:13	19:17	14:10 15:22	56:18 57:4 58:1
4:10 55:6,17	look 11:24,25	17:8 18:21,22	58:5
56:5,22	11:25 12:1	18:24 19:4,5,11	mark 5:15 25:3
<b>lead</b> 29:3	13:18 18:20	19:20,21,24	marked 5:18
leadership	19:1 28:8 31:3	20:9 22:8 31:1	13:19 15:11,15
31:14,15 39:17	38:1 40:11	mails 16:9 19:19	23:1 25:5 42:8
41:15		19:22	42:10
		ral Solutions	

### [marstiller - okay]

491 04 4 6	41.05.45.10	111	47.00.05.50.0
marstiller 31:16	41:25 45:12	necessary 11:1	47:20,25 53:3
41:9	48:4,6,19 52:22	12:3,8 21:1	objection 44:22
matter 4:5 44:2	mention 32:5	necessity 9:3	occurred 15:6
<b>matthew</b> 1:8 3:2	40:22	<b>need</b> 13:14 14:2	offhand 13:9
4:4 5:6 48:25	mercer 1:13	18:17 36:7	18:18
49:4 53:18 55:8	4:10 54:1 55:6	<b>needed</b> 11:20,20	<b>office</b> 25:11
56:8 57:5,25	55:17 56:5,22	26:2 28:1 29:18	40:5 41:14
58:2,5,6	<b>method</b> 52:16	37:1,2	49:14,16,24,25
mckee 2:14 4:21	methods 32:20	needs 12:4 14:6	51:2
mean 13:24	<b>mid</b> 21:24	53:2	officially 8:1
20:3 34:7 38:7,8	<b>mind</b> 22:3	never 40:6	<b>oh</b> 6:2,16 17:10
38:24 39:1 41:8	minnich 4:10	nevertheless	38:14
50:6 52:11,24	<b>minute</b> 48:22	10:16 12:22	okay 5:11,24
meaning 20:20	missed 34:3	<b>new</b> 8:18 14:6	6:11,13,14,25
30:3	35:9 53:11	23:23	7:2,5,11,20 8:3
means 9:15	misspoke 17:11	nonapplicable	8:6,16,21,23 9:7
16:20 43:1	mistake 6:6	33:20	9:23 10:3,5,5,18
media 37:1	<b>mma</b> 20:18 23:4	northern 1:1	10:23 11:3,10
medicaid 7:9	23:4,11,14,16	<b>notary</b> 55:7,18	11:13,21,21
8:17 10:19 11:5	24:1	56:6	12:14,18,25
11:7 12:14	molina 24:2	<b>notes</b> 56:11	13:4,6,10,18,18
14:25 17:2 23:8	monroe 2:8	<b>notice</b> 7:16,20	14:8,13,21 15:1
42:3 51:25 53:1	<b>move</b> 30:17	7:22,25 18:17	15:7,10,19,24
medical 9:2	n	noticed 49:7	16:5,25 17:4,15
12:1 23:5,7		notification 3:7	17:19 18:2,6,6
24:11,16 51:20	n 2:1 3:1,17 4:1	0	18:11,19,21
52:25	nabd 7:21		19:5,10,23
medically 10:25	name 4:10	o 3:17 4:1 58:2	20:23 21:3,9,16
12:8 21:1	nationally 36:25	oath 3:4 55:1	21:21 22:13,18
meet 41:18	<b>nature</b> 30:4	obfuscating	22:20,21 23:4,7
memo 13:23,25	46:24	34:12	23:16 24:11,25
14:4,9 18:2,4	ndc 14:6	object 30:23	24:25 25:9 27:5
25:7 26:2 27:9	ndcs 17:6	33:1 36:22	28:8,19,19
27:21 28:1 29:6	necessarily 16:1	37:12 39:22	29:21 30:10
34:9 39:6 41:17	16:3 52:11	43:22 44:12	31:18,21 32:3,8
		45:11,25 46:19	, , , , , , , , , , , , , , , , , , , ,
	Varitant I as	101	

[okay - policies] Page 69

32:13 33:4,22	original 58:12	<b>pas</b> 9:25 10:1	12:15
34:3,7,21 35:1,4	<b>outside</b> 49:18,20	<b>ped</b> 10:11	<b>phone</b> 4:23
35:12 36:1,9,14	49:25 50:2	pediatrics 26:11	phonetic 41:5
36:20 38:6,13	overcome 33:13	penalties 57:22	physically 9:17
38:17,22 39:17	overpayments	percentage 13:6	<b>pi</b> 8:19
39:20 40:5,5,8	11:19	perfectly 39:20	<b>pick</b> 26:13
40:14,21 41:2,6	overturning	<b>period</b> 23:19,23	pickle 31:8
41:11,14,17,17	30:17	24:13,17	place 1:11
42:5,19 46:10	р	perjury 57:22	places 49:8
48:20,21,23	<b>p</b> 2:1,1 3:17 4:1	<b>perko</b> 2:7 4:18	plainitiff's 5:17
50:10,20,23,25	10:15	4:18 6:2 14:15	plaintiff 2:6
51:8,14,23 52:4	pa 7:12,15,17	14:18 19:13	plaintiff's 3:10
52:14,23 53:9	8:9,10,15,19 9:8	20:5 30:23 33:1	13:19 15:11,15
53:12,17	9:9,10,18 10:2,3	36:22 37:12	23:2 25:4 42:7
once 20:20	·	39:22 40:23	53:12
38:17 58:13	10:4,6,7,8,14,15	43:22 44:12,17	plaintiffs 1:4
ones 24:3	12:19,20,21 13:4	44:22 45:11,25	4:15,17,20 6:23
operated 24:7		46:19 47:8,20	25:16
24:14,15	pa'd 7:19,25	47:25 53:3,14	<b>plans</b> 23:12,13
<b>opinion</b> 30:13	<b>page</b> 3:11 6:8	53:24 58:2,18	23:14,16 24:1,7
30:14,15 36:10	7:2,4 10:7,12	person 8:16	24:9
36:12	17:10 57:6	30:19,25 43:6	<b>please</b> 4:12,13
opinions 30:22	pages 23:25	54:2	4:24 50:25 52:6
opportunity	29:15 56:10	personal 21:14	54:5 58:8
8:17	paid 11:11,23	21:17 30:13	<b>point</b> 11:4,6
order 45:23	13:7	personally 55:8	17:7 19:12 20:5
46:10	part 5:14	peterson 19:16	27:18 28:20
ordering 58:9	particular 14:9	peterson's	33:10 34:11
58:13,13	21:16 26:15	19:19	35:8,12,14
organization's	particularly	pharmacist 22:3	36:15,17,21
31:6	25:22 29:13	pharmacists	37:22 38:10,10
organizations	<b>parties</b> 3:19	21:19,22 22:1	38:15
25:23 26:7	56:13,14 58:9	pharmacy 7:18	<b>points</b> 33:21
organized 54:2	58:13	7:22,23 8:22	policies 50:5,6
8	<b>party</b> 58:13	12:9,10,10,12	50:12,14,16,17
		· · · · · · · · · · · · · · · · · · ·	
		ral Solutions	

### [policy - publicly]

74 110 -	AT 0.44		a
<b>policy</b> 14:25	prescriber 8:11	procedures 30:8	promulgation
46:14 49:11,13	12:13	proceedings	17:21 30:18
49:21 50:1,11	prescribing 8:7	1:11	<b>proof</b> 43:17
<b>poorly</b> 30:4,7,12	8:8	process 8:2,9	44:18,23
32:15,24 33:23	prescription	10:15 11:4,6	<b>prove</b> 42:13
34:22	8:12,13,14,18	12:6,21 13:4	43:13 44:15,21
<b>pos</b> 34:19	13:6	26:5 27:22	45:1,2,3,6,8
<b>pose</b> 36:18	present 2:11	41:22 42:21,22	proven 43:7
position 30:10	35:1	43:2,24,25 44:5	provide 14:17
31:6 33:12,15	presented 31:14	44:8 45:18,22	22:18 28:16
34:17,19 36:20	<b>press</b> 29:17	46:21,24 50:15	33:19 35:5
37:9 47:13	prestige 24:2	51:2	40:12 41:8
49:10 51:19,23	presumes 41:18	processes 50:19	provided 5:12
51:24 52:14,25	pretty 9:15	50:20	6:7 10:8 14:8,11
possibility 13:1	29:16 31:13	processing 14:3	14:21 15:21
possible 27:16	38:6	procurement	20:15 25:15
49:19	previous 36:23	23:21	26:18 28:23
<b>posted</b> 15:2,25	37:16	produced 5:7	29:9 30:1,2,11
16:2,6	previously	55:9	41:11 58:8
posting 16:4	13:19 15:11,15	product 39:24	provider 8:7
potential 26:3	23:1 29:21 32:8	40:3	10:10,15 12:20
potentially 13:2	46:20	products 16:25	providing 50:11
19:8 21:13,14	<b>prim</b> 16:20	17:16	provision 51:25
21:19 22:5	<b>prior</b> 8:2,9,19	professional	psychotherapy
42:12	8:24 9:11,11,13	55:6,17 56:5,22	51:16 52:9,17
preceding 18:16	9:16,18,21	program 9:20	52:19 53:2,5
preclude 16:3	10:13,24,25	10:19 16:18	pubertal 15:18
preferred 6:15	13:14 14:23	23:8	<b>puberty</b> 20:1,12
prepare 29:5	<b>pro</b> 8:7 10:10	programming	<b>public</b> 3:13 25:1
prepared 28:22	12:12	16:11,18	26:18 28:20,23
preparing 36:14	probably 19:22	programs 23:9	29:1,3,25 55:7
prescribed 7:9	35:22 53:8	project 2:3	55:18 56:6
10:10,13,24,25	procedure	promulgated	publicly 15:1,7
12:5,7	58:23,24	50:14	15:24 16:1,4
			23:17 25:24,25

#### [published - request]

published 29:17	reality 34:20	<b>record</b> 6:20 7:8	release 27:17
pulled 19:22	realize 38:14	49:1 53:20,25	29:18
purely 39:23	really 33:10	54:3 56:11	released 25:25
40:3	46:22	recorded 4:4	36:25
	reason 11:1	22:2 48:24 49:3	remember
<b>purpose</b> 25:19 36:9	29:22 32:24	53:18	10:21
put 29:15 40:9	49:10 50:10	redetermine	reminder 16:17
<b>put</b> 29.13 40.9	57:6	29:10 36:4	remote 1:11
q		referenced	remote 1.11 removal 16:10
quality 35:15	reasonable 58:11	14:10 15:22	
question 6:5,7		58:7	remove 17:5,12 18:7
7:13 28:9 52:2,6	reasoned 28:16		
52:23,24	29:14,24 30:4,7 30:12 32:15,24	references 23:4	removed 16:17 16:22
questioning	· · · · · · · · · · · · · · · · · · ·	referencing	
32:19	33:23 34:23	18:22 19:25	repeat 52:6
questions 5:13	reasoning 29:9	23:11,12,14	rephrase 34:4
11:3 53:10,14	33:8	referred 9:16	report 26:16
<b>quick</b> 7:14 10:6	rebuttal 31:3	34:15	27:18,19,20,23
12:18	32:10 33:6 34:9	refill 8:12,13	28:3,4,10 29:16
<b>quite</b> 52:23	recall 11:1,2	reflect 17:25	29:17,18,24
r	15:6	reflective 50:18	30:12,17,20
<b>r</b> 2:1 4:1	receipt 58:10	refute 35:11	31:19,22,23
<b>r.l.</b> 4:10	receive 7:15,20	36:15,21 37:10	35:7 36:9,15
raise 4:24	7:24 8:4 25:21	37:17	37:10,17 38:23
	45:9	refuting 37:21	39:5 40:6,8,19
<b>read</b> 6:9 9:5 16:6 30:25	received 25:14	regard 58:11	40:21 56:7
	38:25 58:13	regardless 44:3	reported 1:13
37:24 38:8,10	receiving 35:25	regards 52:20	reporter 4:9,13
38:12,24,25	recipient 7:18	regulation	4:24 5:5 6:20,24
40:18 57:22	11:25 12:4	41:18	53:21 54:4 55:6
58:8	44:19,24 45:14	reimbursed	55:17 56:1,5,22
reading 3:20	recipients 20:16	12:3,15	reports 29:5
38:3,7,9,18	recognize 5:20	reissue 8:14	represents
58:20	recollect 18:13	relates 46:15	15:20
real 10:6 12:18	reconsider 29:4	relative 56:12	request 8:8
		56:14	10:14 12:19
		val Calutions	

#### [request - several]

19:9,11,11	27:24 31:14	23:25 36:11	secretary 31:16
20:15 24:20	35:10 51:9	37:11 49:6	41:9
41:13 43:4	rest 10:20	53:12	see 17:10 25:16
44:11 45:17,23	resubmit 8:8	<b>rivaux</b> 2:13 4:21	27:13 51:1
46:15,23	result 17:15	<b>role</b> 19:16 27:3	seeking 46:16
requested 56:9	resulted 16:25	<b>rubin</b> 22:6	46:16
requester 46:6	<b>retro</b> 11:5	<b>rule</b> 18:10 25:11	select 11:14
46:12 47:16,19	retrospective	26:23,25 28:6	<b>send</b> 14:4 41:2,6
requesting 50:8	10:20,23 11:4,6	28:17 30:18	54:1
53:21	11:10,14,16,18	44:2 45:4,15	sensationalist
requests 14:23	11:22 12:6 13:7	47:14,14 58:23	29:16,20 30:4
19:25 20:16,24	13:15,16	58:24	sent 20:21,24
47:13	returned 20:22	rulemaking	25:24 26:14
require 10:24	<b>review</b> 9:9,14	43:25 50:9,15	27:12 40:21
required 10:16	9:24 10:20,23	<b>rules</b> 58:11	41:4 42:11
12:22 20:2,17	11:4,6,10,13,14	running 21:5	<b>serve</b> 25:20
requirement	11:18,22 12:6	S	serves 20:12
24:19 41:19	13:4,7,15 31:3	s 2:1,8 3:17,17	45:12
research 30:9	36:3,10 40:12	4:1	service 43:7
38:1	41:10 43:2	satisfy 43:17	44:21 46:6,11
reserved 3:21	45:17 46:21	saving 28:13	46:16 47:15,19
resolved 51:16	49:15 56:8 58:8	36:16,18 37:11	47:22
52:9	58:10	37:14,18 42:12	services 12:2
respective 3:19	reviewed 9:22	43:23	15:17 24:11,16
<b>respond</b> 26:4,17	9:22 20:21	says 23:11 42:20	34:14 41:18,20
28:8	31:10,11 51:10	44:2	41:23 42:14,23
responding	reviewing 9:17	scenario 52:3,4	43:10,20 44:16
28:23	14:22 37:25	scene 52:3	45:6,9 48:5,7,16
response 3:13	49:7	scene 32.3 scratch 15:14	48:18 51:24
7:12 25:1,13	reviews 9:12	18:22 46:3	54:2
26:19 27:15	11:16 13:16	scrutiny 32:19	<b>set</b> 7:14 30:22
28:24 32:2	<b>rh</b> 1:5 4:6 57:4	search 19:19	<b>seven</b> 15:3
responses 3:12	richmond 2:3	searches 19:21	42:24
5:12,15,22 10:9	<b>right</b> 4:24 7:11	second 6:5,19	several 4:19
13:22 26:8	10:18 16:7	24:17	

[sex - summary] Page 73

15.0	• • • • • • • •		
sex 17:2	situation 11:17	staff 15:4 28:2	<b>street</b> 2:3,8
<b>shake</b> 38:15	21:4 34:20 43:9	31:3,5	strictly 43:11
<b>shani</b> 2:13 4:21	situations 42:13	<b>stand</b> 23:5	subject 13:15
<b>share</b> 21:22	43:19 44:10	standard 30:8	submit 8:18
28:1	47:18 48:16,18	32:20 34:13,15	10:15 12:20
shared 21:11	<b>small</b> 27:24	34:17	29:5
sheeran 2:12	<b>society</b> 26:9,10	<b>stands</b> 13:23	submitted 27:14
4:22,22	27:5 29:3,13	51:11	29:3
<b>sheet</b> 3:6,15	30:11,21 36:16	<b>start</b> 32:20	subpart 41:23
42:6,11,12,19	37:18	36:20 38:11	42:24 43:15,20
46:4 49:7,17	society's 34:22	39:7	46:17 47:4
50:3 51:11 57:1	solemnly 5:1	started 6:5	substance 37:2
58:8	solutions 58:17	starting 32:14	substantial
<b>shortly</b> 37:24	<b>sorry</b> 6:18 11:21	37:9	25:21 26:1,15
38:6	15:14 26:9 32:3	state 17:2 55:3,7	45:3,8,9,16
<b>show</b> 6:9 10:15	41:17 52:4	55:18 56:2,6	substantiated
12:21	<b>sort</b> 7:22	<b>stated</b> 57:22	28:12 29:14,25
<b>side</b> 53:13	southernlegal	statement 51:17	substitute 49:9
<b>sign</b> 58:8	2:5	51:19 52:19	suffering 52:15
signature 55:16	<b>speak</b> 20:13	statements	53:1
56:21 58:22	39:2 46:23	26:21,22 28:16	sufficient 30:16
signed 55:11	50:22 52:18	37:2 50:6	sufficiently
signing 3:20	speaking 6:21	states 1:1 19:24	35:10,11 36:8
58:20	43:16	20:11	suggested 58:10
similar 34:24	special 15:17	statute 58:11	suggestion
<b>simone</b> 2:2 4:16	specialty 24:7,9	statutes 50:7	31:25 32:9,11
53:11	specific 12:4	staywell 24:2,6	39:24
simone.chriss	17:7 20:5 44:11	24:18	summaries
2:5	specifically	ste 2:8	26:25
<b>simply</b> 32:24	16:15	stenographic	summarize
sincerely 58:15	speculating	56:11	25:14 36:10
single 11:11	44:13	stenographica	summarizing
sir 4:24	speculation	1:13 56:7	28:23
<b>sit</b> 47:2	43:5 46:25	stipulated 3:18	summary 3:13
		_	24:25 25:12

#### [summary - university's]

20.22.22.2		22.10.21.11	
29:23 39:6,7,9	<b>tamayo</b> 31:17	23:19 24:1,14	turning 7:11
39:18	<b>team</b> 50:4	38:3 48:25 49:4	13:7 16:9 19:23
sunshine 24:2,6	tell 7:24 16:12	50:22 53:19,22	24:25 49:6
supervisor 31:7	40:9,18 47:2	<b>titled</b> 6:15	<b>two</b> 49:3
support 29:5	telling 13:22	today 5:2 47:2	<b>type</b> 21:12
34:5 35:2,6 37:8	term 23:12	today's 4:8	u
37:8	testified 5:8	together 29:15	<b>u</b> 3:17
supported	10:19 15:10	took 24:18	<b>uh</b> 15:13,23
33:14,16,17	testimony 3:2	top 24:3	16:14 17:23
supposed 25:20	5:1 11:1 36:24	towards 26:16	23:20,22 31:12
suppression	37:16 46:8	37:20	44:9 51:6
15:18	51:12,13	transcript 3:5	<b>um</b> 35:15 49:11
<b>sure</b> 19:15	<b>text</b> 43:1	3:21 6:10 51:10	49:15
27:15 29:19	thank 5:5 6:2,24	56:9,10 57:2	under 9:18
37:1,3 49:19	7:11 13:22	58:7,8,10,12,14	10:16 12:22
<b>susan</b> 16:16	14:16,19 53:16	58:21	13:1,3 37:9 43:2
20:10 22:6,7,10	<b>that'd</b> 31:7 43:5	transcripts 58:9	· · · · · · · · · · · · · · · · · · ·
22:12	therapy 20:14	<b>treat</b> 10:11	44:10 45:4 48:6
suspected 11:17	thing 6:6 35:19	42:15,24 43:20	57:22 58:11
suspicion 11:19	35:23 36:1	46:17 48:17	<b>undergo</b> 13:7
swear 4:13 5:1	things 14:6	treatment 20:1	45:17
<b>sworn</b> 5:7 55:9	28:15	20:25 24:22	understand
symptoms 18:5	<b>think</b> 12:11	36:7,8 42:2,14	9:24 31:21 44:7
system 14:2,5	21:18,23 24:3	43:14 46:16	45:20,20 46:14
t	29:12 35:9,22	48:13 51:4,5	understanding
	36:5	52:10,11,16,20	8:3,5 13:13
t 3:17,17	thinking 30:8	53:2	27:19
take 8:18 12:14	thought 32:8	treatments	undertakes
18:9 19:1 33:10	33:13	51:20 52:21	10:20
48:21 53:24	three 25:22 26:7	trouble 37:13	unit 10:19
talked 5:24	26:10,13,14,19	true 56:10 57:23	united 1:1
talking 35:19,20	34:25 35:17	truth 5:2,3,3	university 26:8
50:14,16 53:4	thrust 33:16	try 45:16	26:10
tallahassee 1:2	time 1:10 4:9	trying 9:23 35:8	university's
2:8 4:8	14:24 22:6,7	35:13 46:14	27:4
	17.27 22.0,1	33.13 70.17	
	1	ral Calutions	1

#### [update - yesterday]

			T
<b>update</b> 14:2,5	<b>verbal</b> 19:8,11	<b>web</b> 6:8 7:2,4	writing 37:10
18:5	25:14	23:25	written 3:12
updated 17:24	verbally 7:23	website 16:6	5:12 7:13,24 8:4
<b>ups</b> 7:14	<b>vergil</b> 2:7 58:2	23:17	8:4 10:9 13:22
<b>url</b> 6:9 7:8 9:4	58:18	wednesday 1:9	25:12,13,21
use 8:25 9:4	<b>verify</b> 19:10	<b>weida</b> 1:6 4:5	26:18,25 39:20
11:22 14:5,22	veritext 58:17	57:3	41:25 47:12
18:4 20:1,12,14	veritext.com	welcome 45:16	50:8,12,20 51:2
24:21,23 27:19	58:9	went 18:10 38:9	<b>wrong</b> 28:13
27:20 28:4,5	<b>vet</b> 24:20	<b>western</b> 32:1,7	38:19
30:6 36:24	<b>vetted</b> 20:2 22:1	williams 16:16	wrote 25:7,8
42:20,21	<b>vetting</b> 20:17,19	20:11 22:6,7,10	31:22 37:16
<b>used</b> 11:7 19:16	<b>video</b> 4:4 48:23	22:12	47:17
48:11,13,17	48:24 49:3,3	<b>wilson</b> 16:15	X
using 8:9 22:22	53:18	20:10	<b>x</b> 3:1
usually 26:20	videographer	witness 4:13 5:4	
v	4:3,11 48:23	5:7 19:15 30:24	y
v 1:5 4:5	49:2 53:15,17	33:2 36:23	<b>yale</b> 26:8,10
valid 17:2 32:17	vogel 2:7	37:13 39:23	27:4,6 29:2,13
33:7,8,8,9	<b>vs</b> 57:3	40:24 43:23	29:15 30:11,20
, , , ,	W	44:13,18,23	32:2,14 33:15
<b>validity</b> 26:1 28:4,9	waive 58:20	45:12 46:20	33:16 34:10
vanmeter 41:4	waiver 42:20,22	47:9 53:4	35:7 36:15
vanmeter 41.4 vanmol 31:25	<u> </u>	<b>words</b> 32:19	37:18 38:9
	45:21,22 46:15	33:13 47:17	yale's 34:24
32:4,5 39:25	47:14 58:19	49:9	<b>yeah</b> 6:13 9:3
40:14 41:4	walk 33:11	work 6:8 21:22	19:2,20 35:21
vanmol's 32:9	want 10:5	31:11 39:23	37:16 38:20
variance 42:20	wanted 6:5,8	40:3	40:4
42:21 43:9,24	27:13,15	worked 31:24	years 15:4
44:11 45:5,17	warrant 30:16	works 13:25	<b>yep</b> 16:13,13
45:22,23 46:10	way 6:10 21:24	worthy 35:24	yesterday 42:11
46:15,21,24	33:18 46:13	write 57:2	49:7
47:3,13	we've 19:21	<b>writes</b> 16:16	
variances 44:2	24:20 52:12		
50:8 51:3			

[zoom - zoom] Page 76

	Z	
zoom	53:15	

# Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

## VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.